US20060235027A1 - Inhibitors of cdc25 phosphatases - Google Patents
Inhibitors of cdc25 phosphatases Download PDFInfo
- Publication number
- US20060235027A1 US20060235027A1 US11/410,659 US41065906A US2006235027A1 US 20060235027 A1 US20060235027 A1 US 20060235027A1 US 41065906 A US41065906 A US 41065906A US 2006235027 A1 US2006235027 A1 US 2006235027A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- ethyl
- amino
- methyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000007588 cdc25 Phosphatases Human genes 0.000 title claims abstract description 16
- 108010046616 cdc25 Phosphatases Proteins 0.000 title claims abstract description 16
- 239000003112 inhibitor Substances 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 133
- 238000000034 method Methods 0.000 claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract 4
- -1 benzyloxycarbonylamino Chemical group 0.000 claims description 167
- 125000000217 alkyl group Chemical group 0.000 claims description 97
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 90
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 125000001072 heteroaryl group Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 43
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 42
- 125000003545 alkoxy group Chemical group 0.000 claims description 41
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 201000004384 Alopecia Diseases 0.000 claims description 27
- 231100000360 alopecia Toxicity 0.000 claims description 27
- 125000001188 haloalkyl group Chemical group 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000004414 alkyl thio group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- VTZZFHYCFVDZRI-UHFFFAOYSA-N 4-(dimethylamino)-2-[[methyl-[2-(4-nitrophenyl)ethyl]amino]methyl]phenol Chemical compound CN(C)C1=CC=C(O)C(CN(C)CCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 VTZZFHYCFVDZRI-UHFFFAOYSA-N 0.000 claims description 12
- NIBQRACPBDUFHM-UHFFFAOYSA-N [4-(dimethylamino)-2-methoxy-6-[[methyl-[2-(4-nitrophenyl)ethyl]amino]methyl]phenyl] acetate Chemical compound COC1=CC(N(C)C)=CC(CN(C)CCC=2C=CC(=CC=2)[N+]([O-])=O)=C1OC(C)=O NIBQRACPBDUFHM-UHFFFAOYSA-N 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- PMHFBOAKGMQKPW-UHFFFAOYSA-N 2-[[methyl-[2-(4-nitrophenyl)ethyl]amino]methyl]benzene-1,4-diol Chemical compound C=1C(O)=CC=C(O)C=1CN(C)CCC1=CC=C([N+]([O-])=O)C=C1 PMHFBOAKGMQKPW-UHFFFAOYSA-N 0.000 claims description 11
- ABNKZFGXQDWOCH-UHFFFAOYSA-N 3,7-dihydroxy-n-[[3-(4-methylpiperidin-1-yl)sulfonylphenyl]methyl]naphthalene-2-carboxamide Chemical compound C1CC(C)CCN1S(=O)(=O)C1=CC=CC(CNC(=O)C=2C(=CC3=CC=C(O)C=C3C=2)O)=C1 ABNKZFGXQDWOCH-UHFFFAOYSA-N 0.000 claims description 11
- GOKYHQGRIIXMNE-UHFFFAOYSA-N 4-(dimethylamino)-2-methoxy-6-[[methyl-[2-(4-nitrophenyl)ethyl]amino]methyl]phenol Chemical compound COC1=CC(N(C)C)=CC(CN(C)CCC=2C=CC(=CC=2)[N+]([O-])=O)=C1O GOKYHQGRIIXMNE-UHFFFAOYSA-N 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- WFLMTOKWHNPHCD-UHFFFAOYSA-N 2-(dimethylamino)-6-methoxy-4-[[methyl-[2-(4-nitrophenyl)ethyl]amino]methyl]phenol Chemical compound CN(C)C1=C(O)C(OC)=CC(CN(C)CCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 WFLMTOKWHNPHCD-UHFFFAOYSA-N 0.000 claims description 10
- FQWIKSOIQKEKSD-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-[[3-(trifluoromethyl)phenyl]sulfonylamino]phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)NCCC(C=C1)=CC=C1NS(=O)(=O)C1=CC=CC(C(F)(F)F)=C1 FQWIKSOIQKEKSD-UHFFFAOYSA-N 0.000 claims description 10
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 230000002269 spontaneous effect Effects 0.000 claims description 10
- HVRKWBHTTRXSRK-UHFFFAOYSA-N (3,7-dihydroxynaphthalen-2-yl)-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C(=CC3=CC=C(O)C=C3C=2)O)CC1 HVRKWBHTTRXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 9
- JHCZISDGOQOVKV-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-(4-sulfamoylphenyl)ethyl]naphthalene-2-carboxamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)C1=CC2=CC(O)=CC=C2C=C1O JHCZISDGOQOVKV-UHFFFAOYSA-N 0.000 claims description 8
- KZBVXAVMDMWNKX-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-(methanesulfonamido)phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CCNC(=O)C1=CC2=CC(O)=CC=C2C=C1O KZBVXAVMDMWNKX-UHFFFAOYSA-N 0.000 claims description 8
- YKRFGHVNMWYJCF-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-[(4-methylphenyl)sulfonylamino]phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C=C1)=CC=C1CCNC(=O)C1=CC2=CC(O)=CC=C2C=C1O YKRFGHVNMWYJCF-UHFFFAOYSA-N 0.000 claims description 8
- QYLJAQYCWCNDAI-UHFFFAOYSA-N 4-(dimethylamino)-2-[[2-(4-nitrophenyl)ethylamino]methyl]phenol Chemical compound CN(C)C1=CC=C(O)C(CNCCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 QYLJAQYCWCNDAI-UHFFFAOYSA-N 0.000 claims description 8
- PBKWFQXZOSIIAD-UHFFFAOYSA-N 4-(dimethylamino)-2-methoxy-6-[[2-(4-nitrophenyl)ethylamino]methyl]phenol Chemical compound COC1=CC(N(C)C)=CC(CNCCC=2C=CC(=CC=2)[N+]([O-])=O)=C1O PBKWFQXZOSIIAD-UHFFFAOYSA-N 0.000 claims description 8
- MBPDGAYNZBGADZ-UHFFFAOYSA-N n-[2-[4-(butylsulfonylamino)phenyl]ethyl]-3,7-dihydroxynaphthalene-2-carboxamide Chemical compound C1=CC(NS(=O)(=O)CCCC)=CC=C1CCNC(=O)C1=CC2=CC(O)=CC=C2C=C1O MBPDGAYNZBGADZ-UHFFFAOYSA-N 0.000 claims description 8
- CQTDVDBFPSMFRR-UHFFFAOYSA-N n-[2-[4-[(4-fluorophenyl)sulfonylamino]phenyl]ethyl]-3,7-dihydroxynaphthalene-2-carboxamide Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)NCCC(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(F)C=C1 CQTDVDBFPSMFRR-UHFFFAOYSA-N 0.000 claims description 8
- VZKJJWDRMSDGJZ-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-(4-nitrophenyl)ethyl]naphthalene-2-carboxamide Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)NCCC1=CC=C([N+]([O-])=O)C=C1 VZKJJWDRMSDGJZ-UHFFFAOYSA-N 0.000 claims description 7
- ZBMWGZBMTHAGSU-UHFFFAOYSA-N n-[[4-(dimethylamino)phenyl]methyl]-3,7-dihydroxynaphthalene-2-carboxamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)C1=CC2=CC(O)=CC=C2C=C1O ZBMWGZBMTHAGSU-UHFFFAOYSA-N 0.000 claims description 7
- FXHADQJMIJZCQJ-UHFFFAOYSA-N (3,7-dihydroxynaphthalen-2-yl)-(4-methylsulfonylpiperazin-1-yl)methanone Chemical compound C1CN(S(=O)(=O)C)CCN1C(=O)C1=CC2=CC(O)=CC=C2C=C1O FXHADQJMIJZCQJ-UHFFFAOYSA-N 0.000 claims description 6
- AHEQWNGHWSENKP-UHFFFAOYSA-N (4-butylsulfonylpiperazin-1-yl)-(3,7-dihydroxynaphthalen-2-yl)methanone Chemical compound C1CN(S(=O)(=O)CCCC)CCN1C(=O)C1=CC2=CC(O)=CC=C2C=C1O AHEQWNGHWSENKP-UHFFFAOYSA-N 0.000 claims description 6
- BUNZXSCGNZBZRI-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-(naphthalen-1-ylsulfonylamino)phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C1=CC=C2C(S(=O)(=O)NC3=CC=C(C=C3)CCNC(=O)C=3C(O)=CC4=CC=C(C=C4C=3)O)=CC=CC2=C1 BUNZXSCGNZBZRI-UHFFFAOYSA-N 0.000 claims description 6
- MOBXUFHHWVLBGT-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-(thiophen-2-ylsulfonylamino)phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)NCCC(C=C1)=CC=C1NS(=O)(=O)C1=CC=CS1 MOBXUFHHWVLBGT-UHFFFAOYSA-N 0.000 claims description 6
- AMBXCQONWVGOHB-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-[(1-methylimidazol-4-yl)sulfonylamino]phenyl]ethyl]naphthalene-2-carboxamide Chemical compound CN1C=NC(S(=O)(=O)NC=2C=CC(CCNC(=O)C=3C(=CC4=CC=C(O)C=C4C=3)O)=CC=2)=C1 AMBXCQONWVGOHB-UHFFFAOYSA-N 0.000 claims description 6
- ZUASGOPWZDWVKD-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-[(4-methoxyphenyl)sulfonylamino]phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC(C=C1)=CC=C1CCNC(=O)C1=CC2=CC(O)=CC=C2C=C1O ZUASGOPWZDWVKD-UHFFFAOYSA-N 0.000 claims description 6
- NERVKDFTUQRHOU-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-[(4-nitrophenyl)sulfonylamino]phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)NCCC(C=C1)=CC=C1NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 NERVKDFTUQRHOU-UHFFFAOYSA-N 0.000 claims description 6
- BYLKHFKESURAHC-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-[[2-(trifluoromethyl)phenyl]sulfonylamino]phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)NCCC(C=C1)=CC=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F BYLKHFKESURAHC-UHFFFAOYSA-N 0.000 claims description 6
- IAYBGMHMPHPOFJ-UHFFFAOYSA-N 3,7-dihydroxy-n-[2-[4-[[4-(trifluoromethyl)phenyl]sulfonylamino]phenyl]ethyl]naphthalene-2-carboxamide Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)NCCC(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 IAYBGMHMPHPOFJ-UHFFFAOYSA-N 0.000 claims description 6
- YYWGAJWMZROHPZ-UHFFFAOYSA-N 4-(4-aminophenyl)-n-[4-(4-methylpiperazin-1-yl)phenyl]butanamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(=O)CCCC1=CC=C(N)C=C1 YYWGAJWMZROHPZ-UHFFFAOYSA-N 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- GCQKBXUCMPWSGP-UHFFFAOYSA-N n-[2-[4-(benzylsulfonylamino)phenyl]ethyl]-3,7-dihydroxynaphthalene-2-carboxamide Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)NCCC(C=C1)=CC=C1NS(=O)(=O)CC1=CC=CC=C1 GCQKBXUCMPWSGP-UHFFFAOYSA-N 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- ARXHLBGFDBXDPZ-UHFFFAOYSA-N n-[2-(4-aminophenyl)ethyl]-3,7-dihydroxynaphthalene-2-carboxamide Chemical compound C1=CC(N)=CC=C1CCNC(=O)C1=CC2=CC(O)=CC=C2C=C1O ARXHLBGFDBXDPZ-UHFFFAOYSA-N 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 201000009613 breast lymphoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 description 131
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 83
- 0 *BN([W])C[Y] Chemical compound *BN([W])C[Y] 0.000 description 76
- 238000010828 elution Methods 0.000 description 35
- 150000001412 amines Chemical class 0.000 description 34
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 201000010099 disease Diseases 0.000 description 26
- 125000005843 halogen group Chemical group 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 238000010586 diagram Methods 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 101150069072 cdc25 gene Proteins 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 14
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 14
- 101150012716 CDK1 gene Proteins 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 230000002062 proliferating effect Effects 0.000 description 13
- 239000012047 saturated solution Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- IOXOZOPLBFXYLM-UHFFFAOYSA-N 2-(4-nitrophenyl)ethanamine Chemical compound NCCC1=CC=C([N+]([O-])=O)C=C1 IOXOZOPLBFXYLM-UHFFFAOYSA-N 0.000 description 8
- GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108091007914 CDKs Proteins 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 7
- 238000010647 peptide synthesis reaction Methods 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 235000012711 vitamin K3 Nutrition 0.000 description 7
- 239000011652 vitamin K3 Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 6
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 208000030852 Parasitic disease Diseases 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 229940041603 vitamin k 3 Drugs 0.000 description 6
- BLLXMTVCTFDWMX-UHFFFAOYSA-N 5-[4-[[amino(thiophen-2-yl)methylidene]amino]phenyl]-n-[2-(dimethylamino)phenyl]pentanamide Chemical compound CN(C)C1=CC=CC=C1NC(=O)CCCCC1=CC=C(\N=C(\N)C=2SC=CC=2)C=C1 BLLXMTVCTFDWMX-UHFFFAOYSA-N 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- 238000005576 amination reaction Methods 0.000 description 5
- 239000000010 aprotic solvent Substances 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 4
- 125000006501 nitrophenyl group Chemical group 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229920005990 polystyrene resin Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QWBZNOKUBXSLRE-UHFFFAOYSA-N 3-O-methylfluorescein 6-phosphate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OP(O)(O)=O)C=C1OC1=CC(OC)=CC=C21 QWBZNOKUBXSLRE-UHFFFAOYSA-N 0.000 description 3
- LBHPPCCDWYBGQF-UHFFFAOYSA-N 5-(dimethylamino)-2-hydroxy-3-methoxybenzaldehyde Chemical compound COC1=CC(N(C)C)=CC(C=O)=C1O LBHPPCCDWYBGQF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 201000009623 Myopathy Diseases 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910005948 SO2Cl Inorganic materials 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 150000003857 carboxamides Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- CLFRCXCBWIQVRN-UHFFFAOYSA-N 2,5-dihydroxybenzaldehyde Chemical compound OC1=CC=C(O)C(C=O)=C1 CLFRCXCBWIQVRN-UHFFFAOYSA-N 0.000 description 2
- KDXNYSZNOWTPLE-UHFFFAOYSA-N 3'-hydroxy-6'-methoxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(OC)=CC=C21 KDXNYSZNOWTPLE-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- WZABSIUWSWFCHJ-UHFFFAOYSA-N 4-(1-methylpiperazin-2-yl)aniline Chemical compound CN1CCNCC1C1=CC=C(N)C=C1 WZABSIUWSWFCHJ-UHFFFAOYSA-N 0.000 description 2
- HQLTZXIDAPHMSY-UHFFFAOYSA-N 4-(4-aminophenyl)-n-[4-(4-methylpiperazin-1-yl)phenyl]butanamide;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(C=C1)=CC=C1NC(=O)CCCC1=CC=C(N)C=C1 HQLTZXIDAPHMSY-UHFFFAOYSA-N 0.000 description 2
- WQMLUHZFRFCQDB-UHFFFAOYSA-N 4-(4-nitrophenyl)butyric acid Chemical compound OC(=O)CCCC1=CC=C([N+]([O-])=O)C=C1 WQMLUHZFRFCQDB-UHFFFAOYSA-N 0.000 description 2
- FXHYHSHSEXIDFE-UHFFFAOYSA-N 5-(dimethylamino)-2-hydroxybenzaldehyde Chemical compound CN(C)C1=CC=C(O)C(C=O)=C1 FXHYHSHSEXIDFE-UHFFFAOYSA-N 0.000 description 2
- BYRQFVGQMJICGG-UHFFFAOYSA-N 5-[4-[[amino(thiophen-2-yl)methylidene]amino]phenyl]-n-[2-(dimethylamino)phenyl]pentanamide;hydrochloride Chemical compound Cl.CN(C)C1=CC=CC=C1NC(=O)CCCCC1=CC=C(\N=C(\N)C=2SC=CC=2)C=C1 BYRQFVGQMJICGG-UHFFFAOYSA-N 0.000 description 2
- WEKFGLUSHCQPGG-UHFFFAOYSA-N 5-[benzyl-[2-[(2,5-diphenyl-1,3-oxazole-4-carbonyl)amino]ethyl]amino]-2-(decanoylamino)-5-oxopentanoic acid Chemical compound C=1C=CC=CC=1CN(C(=O)CCC(NC(=O)CCCCCCCCC)C(O)=O)CCNC(=O)C=1N=C(C=2C=CC=CC=2)OC=1C1=CC=CC=C1 WEKFGLUSHCQPGG-UHFFFAOYSA-N 0.000 description 2
- 101150050673 CHK1 gene Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 229910020889 NaBH3 Inorganic materials 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000021121 meiosis Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- PTPPVTUXJDJAGY-UHFFFAOYSA-N n-methyl-2-(4-nitrophenyl)ethanamine Chemical compound CNCCC1=CC=C([N+]([O-])=O)C=C1 PTPPVTUXJDJAGY-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- JOYRNJIWPUZFBJ-IWTVZHICSA-N (2r)-3-[(1r)-2-[(1r,2r,5s,8as)-1,2,5-trimethyl-5-(4-methylpent-4-enyl)-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]-1-hydroxyethyl]-2-hydroxy-2h-furan-5-one Chemical compound C1([C@H](O)C[C@@]2(C)[C@H]3C([C@](CCC3)(C)CCCC(C)=C)=CC[C@H]2C)=CC(=O)O[C@H]1O JOYRNJIWPUZFBJ-IWTVZHICSA-N 0.000 description 1
- AVASMHZRTFHMNR-UHFFFAOYSA-N (3,7-dihydroxynaphthalen-2-yl)-piperazin-1-ylmethanone Chemical compound C=1C2=CC(O)=CC=C2C=C(O)C=1C(=O)N1CCNCC1 AVASMHZRTFHMNR-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- USZZLTVYRPLBMB-UHFFFAOYSA-N 1,3-dihydroxynaphthalene-2-carboxylic acid Chemical class C1=CC=CC2=C(O)C(C(=O)O)=C(O)C=C21 USZZLTVYRPLBMB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000004899 14-3-3 Proteins Human genes 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N 1H-quinolin-4-one Natural products C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DFFPJGSDZPHLBG-UHFFFAOYSA-N 2-[[3-(4-methylpiperidin-1-yl)sulfonylphenyl]methyl]isoindole-1,3-dione Chemical compound C1CC(C)CCN1S(=O)(=O)C1=CC=CC(CN2C(C3=CC=CC=C3C2=O)=O)=C1 DFFPJGSDZPHLBG-UHFFFAOYSA-N 0.000 description 1
- HJXIRCMNJLIHQR-UHFFFAOYSA-N 2-n,2-n-dimethylbenzene-1,2-diamine Chemical compound CN(C)C1=CC=CC=C1N HJXIRCMNJLIHQR-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 1
- QMWOUSYSNFCKAZ-UHFFFAOYSA-N 3,7-dihydroxynaphthalene-2-carboxylic acid Chemical compound OC1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 QMWOUSYSNFCKAZ-UHFFFAOYSA-N 0.000 description 1
- HULSMIBKPKOBML-UHFFFAOYSA-N 3-(dimethylamino)-4-hydroxy-5-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(N(C)C)=C1O HULSMIBKPKOBML-UHFFFAOYSA-N 0.000 description 1
- QVSSFIWSISZOOW-UHFFFAOYSA-N 3-[[3-[[amino(thiophen-2-yl)methylidene]amino]phenyl]methylamino]-n-[4-(dimethylamino)phenyl]propanamide Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)CCNCC1=CC=CC(N=C(N)C=2SC=CC=2)=C1 QVSSFIWSISZOOW-UHFFFAOYSA-N 0.000 description 1
- NKSZYVGLYYAJEM-UHFFFAOYSA-N 3-[[3-[[amino(thiophen-2-yl)methylidene]amino]phenyl]methylamino]-n-[4-(dimethylamino)phenyl]propanamide;hydrochloride Chemical compound Cl.C1=CC(N(C)C)=CC=C1NC(=O)CCNCC1=CC=CC(N=C(N)C=2SC=CC=2)=C1 NKSZYVGLYYAJEM-UHFFFAOYSA-N 0.000 description 1
- LMRKXSDOAFUINK-UHFFFAOYSA-N 3-chlorosulfonylbenzoic acid Chemical compound OC(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 LMRKXSDOAFUINK-UHFFFAOYSA-N 0.000 description 1
- JZQBAGOECGRTSA-UHFFFAOYSA-N 3-hydroxy-2h-furan-5-one Chemical group OC1=CC(=O)OC1 JZQBAGOECGRTSA-UHFFFAOYSA-N 0.000 description 1
- DNCYPMUASDUGPZ-UHFFFAOYSA-N 3h-1,7-naphthyridin-4-one Chemical class N1=CC=C2C(=O)CC=NC2=C1 DNCYPMUASDUGPZ-UHFFFAOYSA-N 0.000 description 1
- FXNSVEQMUYPYJS-UHFFFAOYSA-N 4-(2-aminoethyl)benzenesulfonamide Chemical compound NCCC1=CC=C(S(N)(=O)=O)C=C1 FXNSVEQMUYPYJS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PDJZOFLRRJQYBF-UHFFFAOYSA-N 4-(aminomethyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(CN)C=C1 PDJZOFLRRJQYBF-UHFFFAOYSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- WOTGLCNRZFHAPS-UHFFFAOYSA-N 5-(4-aminophenyl)-n-[2-(dimethylamino)phenyl]pentanamide Chemical compound CN(C)C1=CC=CC=C1NC(=O)CCCCC1=CC=C(N)C=C1 WOTGLCNRZFHAPS-UHFFFAOYSA-N 0.000 description 1
- ICWKCTNMYJHGIU-UHFFFAOYSA-N 5-(4-nitrophenyl)pentanoic acid Chemical compound OC(=O)CCCCC1=CC=C([N+]([O-])=O)C=C1 ICWKCTNMYJHGIU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101150040313 Wee1 gene Proteins 0.000 description 1
- BEHOKEIMWKGPIP-UHFFFAOYSA-N [3-(4-methylpiperidin-1-yl)sulfonylphenyl]methanamine Chemical compound C1CC(C)CCN1S(=O)(=O)C1=CC=CC(CN)=C1 BEHOKEIMWKGPIP-UHFFFAOYSA-N 0.000 description 1
- GFGISQYOHGESAV-UHFFFAOYSA-N [3-(4-methylpiperidin-1-yl)sulfonylphenyl]methanol Chemical compound C1CC(C)CCN1S(=O)(=O)C1=CC=CC(CO)=C1 GFGISQYOHGESAV-UHFFFAOYSA-N 0.000 description 1
- AYLIEDQYYJIGDP-UHFFFAOYSA-N [C]1=CC=CS1 Chemical compound [C]1=CC=CS1 AYLIEDQYYJIGDP-UHFFFAOYSA-N 0.000 description 1
- RCORNHOUCUDCAC-UHFFFAOYSA-O [NH3+]C(c1ccc[s]1)=Nc1ccccc1 Chemical compound [NH3+]C(c1ccc[s]1)=Nc1ccccc1 RCORNHOUCUDCAC-UHFFFAOYSA-O 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 125000006356 alkylene carbonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- UCDHYFZYUGDETN-UHFFFAOYSA-N cyanophosphonic acid Chemical compound OP(O)(=O)C#N UCDHYFZYUGDETN-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- LOCXWWBDWZENPB-UHFFFAOYSA-N n'-[4-[2-[[5-(dimethylamino)-2-hydroxy-3-methoxyphenyl]methyl-methylamino]ethyl]phenyl]thiophene-2-carboximidamide Chemical compound COC1=CC(N(C)C)=CC(CN(C)CCC=2C=CC(=CC=2)N=C(N)C=2SC=CC=2)=C1O LOCXWWBDWZENPB-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- NQIDKOHVQDRMAW-UHFFFAOYSA-N n-[2-(dimethylamino)phenyl]-5-(4-nitrophenyl)pentanamide Chemical compound CN(C)C1=CC=CC=C1NC(=O)CCCCC1=CC=C([N+]([O-])=O)C=C1 NQIDKOHVQDRMAW-UHFFFAOYSA-N 0.000 description 1
- SRUUNXZYJGBDQC-UHFFFAOYSA-N n-[2-[4-[[amino(thiophen-2-yl)methylidene]amino]phenyl]ethyl]-2,7-dihydroxy-1h-naphthalene-2-carboxamide Chemical compound C1C2=CC(O)=CC=C2C=CC1(O)C(=O)NCCC(C=C1)=CC=C1NC(=N)C1=CC=CS1 SRUUNXZYJGBDQC-UHFFFAOYSA-N 0.000 description 1
- DRCUWEDDQAQBLH-UHFFFAOYSA-N n-[2-[4-[[amino(thiophen-2-yl)methylidene]amino]phenyl]ethyl]-2,7-dihydroxy-1h-naphthalene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=CC(O)=CC=C2C=CC1(O)C(=O)NCCC(C=C1)=CC=C1NC(=N)C1=CC=CS1 DRCUWEDDQAQBLH-UHFFFAOYSA-N 0.000 description 1
- UGMKCCSPWRCINO-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)phenyl]-4-(4-nitrophenyl)butanamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(=O)CCCC1=CC=C([N+]([O-])=O)C=C1 UGMKCCSPWRCINO-UHFFFAOYSA-N 0.000 description 1
- VGJDSNZOPPZCTB-UHFFFAOYSA-N n-methyl-2-(4-nitrophenyl)ethanamine;hydrochloride Chemical compound Cl.CNCCC1=CC=C([N+]([O-])=O)C=C1 VGJDSNZOPPZCTB-UHFFFAOYSA-N 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 125000001624 naphthyl group Chemical class 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical class 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- VSGPVHSTVTXREH-UHFFFAOYSA-N quinolin-4-one Chemical compound C1=CC=C[C]2C(=O)C=CN=C21 VSGPVHSTVTXREH-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- SJKIUZWVSBCLHD-UHFFFAOYSA-N tert-butyl 4-(3,7-dihydroxynaphthalene-2-carbonyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC2=CC(O)=CC=C2C=C1O SJKIUZWVSBCLHD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WVVJGOCFWFSOEG-UHFFFAOYSA-N tert-butyl n-[2-(4-diethoxyphosphoryloxyphenyl)ethyl]carbamate Chemical compound CCOP(=O)(OCC)OC1=CC=C(CCNC(=O)OC(C)(C)C)C=C1 WVVJGOCFWFSOEG-UHFFFAOYSA-N 0.000 description 1
- ILNOTKMMDBWGOK-UHFFFAOYSA-N tert-butyl n-[2-(4-hydroxyphenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=CC=C(O)C=C1 ILNOTKMMDBWGOK-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Definitions
- a subject of the present invention is new inhibitors of cdc25 phosphatases, and in particular of cdc25-C phosphatase.
- Control of the transition between the different phases of the cell cycle during mitosis or meiosis is provided by a group of proteins, the enzymatic activities of which are associated with different states of phosphorylation. These states are controlled by two large classes of enzymes: the kinases and the phosphatases.
- CDKs cyclin-dependent kinases
- Their activities are regulated by their molecular associations with other proteins called cyclins.
- endogenous inhibitors are capable of preventing these activities.
- inhibitors of this family of kinases are already identified and studied in several therapeutic fields such as oncology for preventing the division of tumour cells (McDonald and el-Deiry, Int. J. Oncol .
- CDKs cyclopentase
- kinases such as Wee1 and Mik1 which deactivate the CDKs by phosphorylating certain amino acids (Den Haese et al., Mol. Biol. Cell (1995), 6, 371-385).
- phosphatases such as Cdc25 which activate the CDKs by dephosphorylating tyrosine and threonine residues of CDKs (Gould et al., Science (1990), 250, 1573-1576).
- cyclin B is itself phosphorylated by the Cdc2 kinase (cdk1) to which it is associated (Borgne et al., J. Biol. Chem . (1999), 274, 11977-11986).
- cdc25-A a family of 3 genes, cdc25-A, cdc25-B and cdc25-C, code for the human cdc25 proteins.
- variants originating from alternative splicing of the cdc25B gene have been identified: they are cdc25B1, cdc25B2 and cdc25B3 (Baldin et al., Oncogene (1997), 14, 2485-2495).
- the proteins coded by these variants would be localized differently within the cell (Davezac et al., Oncogene (2000), 19, 2179-2185).
- cdc25 activity is regulated by the Cdc2 and Cdk2 kinases. But in the absence of cdc2 kinase, the activity of cdc25 can be activated by other kinases (Izumi and Maller, Mol. Biol. Cell (1995), 6, 215-226). Among these, the chk1 protein phosphorylates cdc25-C on a serine in position 216, which increases its affinity for a chaperone protein 14-3-3. This bond neutralises cdc25-C and consequently maintains the cdk1 enzyme in a phosphorylated state and therefore inactive, not allowing entry into mitosis.
- the chaperone protein allows the complex to pass into the cytoplasm thanks to a protein unit of nuclear export (Lopez-Girona et al., Nature (1999), 397, 172-175).
- a chemical inhibitor of chk1 allows a cell to continue its cell cycle despite the induction of the DNA break. This aspect allows the effectiveness of certain cytotoxic compounds such as campthotecin to be increased (Jackson et al., Cancer Res . (2000), 60, 566-572).
- cdc25 and principally cdc25-A, appears to prevent the cell from stopping its cell cycle in the event of aggression on the genome and thus avoids a possible repair process (Mailand et al., Science (2000), 288, 1425-1429).
- Vitamin K3 also called menadione
- cdc25 phosphatase was the first selective inhibitor of cdc25 phosphatase described (Ham et al., Bioorg. Med. Chem. Lett . (1998) 8, 2507-2510).
- Other cdc25 inhibitors have since been identified and have an inhibitory activity of micromolar order on the recombinant enzymes. Among these products, the following can be noted:
- a simplified general formula of these compounds could be general formula (ET1): in which A represents a radical which traps free radicals, for example a substituted phenyl radical; X and Y are linking chains, for example alkylene, alkylenecarbonyl, carbonylalkylene radicals; R represents H or alkyl; and B represents a carbocyclic or heterocyclic aryl radical, and preferably the 2-thienyl radical.
- E1 represents a radical which traps free radicals, for example a substituted phenyl radical
- X and Y are linking chains, for example alkylene, alkylenecarbonyl, carbonylalkylene radicals
- R represents H or alkyl
- B represents a carbocyclic or heterocyclic aryl radical, and preferably the 2-thienyl radical.
- the invention offers new inhibitors of cdc25, and in particular of cdc25-C, which correspond to general formula (I) defined below. These compounds are capable of being used as medicaments, in particular in the treatment of the following diseases/disorders:
- the compounds of the present invention are also, because of their properties of inhibiting cdc25 phosphatases, capable of being used to inhibit the proliferation of microorganisms, in particular yeasts.
- One of the advantages of these compounds is their low toxicity on healthy cells.
- A represents an (A1) radical in which two of the R 1 , R 2 , R 3 , R 4 and R 5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio or NR 6 R 7 radical, it being understood moreover that:
- alkyl unless specified otherwise, is meant a linear or branched alkyl radical containing 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms and more preferentially 1 to 6 carbon atoms.
- alkenyl unless specified otherwise, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms and presenting at least one unsaturation (double bond).
- alkynyl unless specified otherwise, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms and presenting at least one double unsaturation (triple bond).
- carbocyclic or heterocyclic aryl is meant a carbocyclic or heterocyclic system comprising at least one aromatic ring, a system being said to be heterocyclic when at least one of the rings which forms it comprises a heteroatom (O, N or S); when a carbocyclic or heterocyclic aryl radical is said to be substituted unless specified otherwise, it is meant that said carbocyclic or heterocyclic aryl radical is substituted 1 to 3 times, and preferably 1 to 2 times by radicals different to a hydrogen atom which, if they are not specified, are chosen from a halogen atom and the alkyl or alkoxy radicals; moreover, unless specified otherwise, by aryl is meant a carbocyclic aryl exclusively.
- haloalkyl is meant an alkyl radical of which at least one (and optionally all) of the hydrogen atoms is replaced by a halogen atom.
- alkylthio, alkoxy, haloalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl, aralkyl is meant respectively the alkylthio, alkoxy, haloalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl, aralkyl radicals the alkyl radical of which has the meaning indicated previously.
- linear or branched alkyl having 1 to 6 carbon atoms is meant in particular the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyl, isopentyl, hexyl, isohexyl radicals.
- carbocyclic aryl is meant in particular the phenyl and naphthyl radicals.
- heterocyclic aryl or heteroaryl is meant in particular the thienyl, imidazolyl, thiazolyl, oxazolyl and pyridyl radicals.
- halogen is meant the fluorine, chlorine, bromine or iodine atoms.
- salt in particular the addition salts with inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or with organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, pamoate, and stearate.
- inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate
- organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, pamoate, and stearate.
- bases such as sodium or potassium hydroxide.
- Salt selection for basic drugs Int. J. Pharm . (1986), 33, 201/217.
- the compounds according to the present invention can contain asymmetrical carbon atoms.
- the compounds according to the present invention have two possible enantiomeric forms, i.e. the “R” and “S” configurations.
- the present invention includes the two enantiomeric forms and all combinations of these forms, including the racemic “RS” mixtures.
- RS racemic
- the compounds of general formula (I) according to the invention will include at least one of the following characteristics:
- the compounds of general formula (I) according to the invention will include at least one of the following characteristics:
- the compounds of general formula (I) according to the invention will include at least one of the following characteristics:
- the compounds of general formula (I) will be used to prepare a medicament intended to treat a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products and radiation-induced alopecia.
- a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products and radiation-induced alopecia.
- the compounds of general formula (I) used for preparing a medicament intended to treat proliferative diseases, parasitic diseases and viral infections are such that the Y radical does not represent the radical of formula (T).
- the compounds of general formula (I) in which the Y radical represents the radical of formula (T) will therefore be preferably used for preparing a medicament intended to treat spontaneous alopecia, alopecia induced by exogenous products, and radiation-induced alopecia
- the compounds of general formula (I) could be used for preparing a medicament intended to treat cancer, and in particular cancer of the breast, lymphomas, cancers of the neck and head, cancer of the lung, cancer of the colon, cancer of the prostate and cancer of the pancreas.
- the compounds of general formula (I) as defined above can be used for preparing a medicament intended to treat spontaneous alopecia, alopecia induced by exogenous products or radiation-induced alopecia.
- the present invention also offers, as medicaments, the compounds of general formula (II) in which A represents an (A1) radical in which two of the R 1 , R 2 , R 3 , R 4 and R 5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio or NR 6 R 7 radical, it being understood moreover that:
- the invention relates, as medicaments, to the following compounds of general formula (II):
- the invention also relates to 5-(4- ⁇ [(1E)-amino (2-thienyl)methylidene]amino ⁇ phenyl)-N-[2-(dimethylamino)phenyl]pentanamide or one of its pharmaceutically acceptable salts, as a medicament.
- compositions comprising, as active ingredient, at least one of the compounds of general formula (II) defined above or a pharmaceutically acceptable salt of such a compound, and preferably a compound chosen from the following compounds:
- a pharmaceutical composition according to the invention will include 5-(4- ⁇ [(1E)-amino(2-thienyl)methylidene]amino ⁇ phenyl)-N-[2-(dimethylamino)phenyl]pentanamide or one of its pharmaceutically acceptable salts.
- composition according to the invention will include, as active ingredient, a compound chosen from the following compounds:
- composition according to the invention will include, as active ingredient, a compound chosen from the following compounds:
- the invention relates moreover to the use of a compound of general formula (II) as defined previously for preparing a medicament intended to treat a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, neurodegenerative diseases, myopathies, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia
- a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, neurodegenerative diseases, myopathies, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia
- the compounds of general formula (II) will be used for preparing a medicament intended to treat a disease chosen from the following diseases: tumorous proliferative diseases and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products and radiation-induced alopecia.
- a disease chosen from the following diseases: tumorous proliferative diseases and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products and radiation-induced alopecia.
- the compounds of general formula (II) could be used for preparing a medicament intended to treat cancer, and in particular cancer of the breast, lymphomas, cancers of the neck and head, cancer of the lung, cancer of the colon, cancer of the prostate and cancer of the pancreas.
- the invention also relates, as new industrial products, to the compounds of general formula (III) in which A represents an (A1) radical in which two of the R 1 , R 2 , R 3 , R 4 and R 5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio or NR 6 R 7 radical, it being understood moreover that:
- the invention also relates, as new products, to the following compounds of general formula (I):
- the invention also relates, as a new industrial product corresponding to general formula (I), to 5-(4- ⁇ [(1E)-amino(2-thienyl)methylidene]amino ⁇ phenyl)-N-[2-(dimethylamino)phenyl]pentanamide.
- the invention also relates to pharmaceutical compositions comprising, as active ingredient, a compound of general formula (III) or a pharmaceutically acceptable salt of the latter.
- Another subject of the invention is the use of compounds of general formula (III) or of pharmaceutically acceptable salts of the latter for preparing medicaments intended to treat a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, neurodegenerative diseases, myopathies; spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia
- the compounds of general formula (III) are used for preparing a medicament intended to treat a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia
- a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia
- the compounds of general formula (III) could be used for preparing a medicament intended to treat cancer, and in particular cancer of the breast, lymphomas, cancers of the neck and head, cancer of the lung, cancer of the colon, cancer of the prostate and cancer of the pancreas.
- the invention also relates to a process for the preparation of a compound of general formula (I).3 in which A, B, W, X, R 20 and R 25 have the same meaning as in general formula (I), said process being characterized in that the compound of general formula (I).2 is reacted with a compound of general formula R 25 —SO 2 Cl in an aprotic solvent (such as tetrahydrofuran, dichloromethane or dimethylformamide) and in the presence of a base (such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base being able if appropriate to also serve as reaction solvent).
- an aprotic solvent such as tetrahydrofuran, dichloromethane or dimethylformamide
- a base such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base being able if appropriate to also serve as reaction solvent.
- the invention also relates to a process for the preparation of a compound of general formula (I).7 in which A, B, W, q and R 30 have the same meaning as in general formula (I), said process being characterized in that the compound of formula (XXVII) is reacted with a compound of general formula R 30 —SO 2 Cl (XXVIII) in an aprotic solvent (such as tetrahydrofuran, dichloromethane or dimethylformamide) and in the presence of a base (such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base being able if appropriate to also serve as reaction solvent).
- an aprotic solvent such as tetrahydrofuran, dichloromethane or dimethylformamide
- a base such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base being able if appropriate to also serve as
- the invention also relates to a process for the preparation of a compound of general formula (I).8 in which A, B, R 17 , R 18 , s, t and R 30 have the same meaning as in general formula (I), said process being characterized in that the compound of formula (XXVII)a is reacted with a compound of general formula R 30 —SO 2 Cl (XXVIII) in an aprotic solvent (such as tetrahydrofuran, dichloromethane or dimethylformamide) and in the presence of a base (such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base being able if appropriate to also serve as reaction solvent).
- an aprotic solvent such as tetrahydrofuran, dichloromethane or dimethylformamide
- a base such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base
- the invention also relates to a process for the preparation of a compound of general formula (I).9 in which A, W, X, R 20 , R 26 and R 27 have the same meaning as in general formula (I), and B represents the —CO— or —CH 2 — radical, said process being characterized in that the amine of general formula (IV) p is reacted with:
- the pharmaceutical composition can be in the form of a solid, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories.
- Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.
- compositions containing a compound of the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups.
- Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.
- the administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by intramuscular injection, etc.
- the administration dose envisaged for a medicament according to the invention is comprised between 0.1 mg and 10 g according to the type of active compound used.
- the compounds of general formula (I) can be prepared for example by the processes described below.
- the compounds of general formula (I) can be prepared from nitrophenyl derivatives of general sub-formula (I).1 according to the procedures represented in Diagram 1 below.
- the reduction of the nitro function can be carried out, for example, by heating the product in an appropriate solvent such as ethyl acetate with a little ethanol in the presence of SnCl 2 ( J. Heterocyclic Chem . (1987), 24, 927-930; Tetrahedron Letters (1984), 25(8), 839-842) or in the presence of SnCl 2 /Zn ( Synthesis . (1996), 9, 1076-1078), using NaBH 4 —BiCl 3 ( Synth. Comm .
- an appropriate solvent such as ethyl acetate with a little ethanol
- SnCl 2 J. Heterocyclic Chem . (1987), 24, 927-930; Tetrahedron Letters (1984), 25(8), 839-842
- SnCl 2 /Zn Synthesis . (1996), 9, 1076-1078
- the compounds of general formula (I) in which Y represents the alkylsulphonylaminophenyl radical can be easily prepared from the compounds of general formula (I).2, Diagram 1, according to standard methods of sulphonamide synthesis, by the action of a sulphonyl halide on an aminated derivative, in an aprotic solvent such as THF, dichloromethane or dimethylformamide (DMF), in the presence of a base such as pyridine, triethylamine or a supported base such as morpholinomethyl polystyrene resin or also by using pyridine as solvent.
- an aprotic solvent such as THF, dichloromethane or dimethylformamide (DMF)
- a base such as pyridine, triethylamine or a supported base such as morpholinomethyl polystyrene resin or also by using pyridine as solvent.
- the derivatives of alkylaminophenyl or dialkylaminophenyl type can be obtained by mono- or dialkylation of the aminophenyl derivatives of general sub-formula (I).2 according to standard methods known to a person skilled in the art.
- Mono-alkylation is carried out by reducing amination with an aldehyde or by nucleophilic substitution by reacting with an R 21 -Hal halogenoalkyl equivalent in order to produce the monoalkylated derivative of general sub-formula (I).5.
- a second alkylation can then be carried out if appropriate by means of an R 22 -Hal halogenoalkyl in order to produce the dialkylated derivative of general sub-formula (I).6.
- the carboxamides of general formula (I), Diagram 3, in which B represents —CO— and A, W, X, R 19 and R 20 are as defined previously, are prepared by condensation of the acids of general formula (V), with the amines of general formula (IV) under standard conditions of peptide synthesis (M. Bodanszky, The Practice of Peptide Synthesis, 145 (Springer-Verlag, 1984)), for example in THF, dichloromethane or DMF in the presence of a coupling reagent such as dicyclohexylcarbodiimide (DCC), 1,1′-carbonyldiimidazole (CDI) ( J. Med. Chem .
- DCC dicyclohexylcarbodiimide
- CDI 1,1′-carbonyldiimidazole
- the amines of general formula (I), Diagram 4, in which B represents —CH 2 — and A, W, X, R 19 and R 20 are as defined previously, are prepared by reaction of the aldehydes of general formula (VI) with amines of general formula (IV) in reducing medium.
- the reaction takes place in an alcoholic solvent such as, for example, methanol, and leads to the imine which is then converted to amine by a reducing agent such as NaBH 4 or NaBH 3 CN or also an Amberlite® IRA-400 borohydride resin (Aldrich; 2.5 mmol BH 4 ⁇ /g of resin).
- the compounds of general formula (I), Diagram 5, in which B represents —NH—CO—(CH 2 ) n — and A, W, X, R 19 , R 20 and n are as defined previously, are prepared by reacting amines of general formula (X) with carboxylic acids of general formula (XI) (in which X′′ is such that X′′—CO ⁇ X) according to methods of peptide synthesis described above or also by reacting the same amines of general formula (X) with aldehydes of general formula (XII) (in which X′ is such that X′—CH 2 ⁇ X) under the conditions of reducing amination described above, or also by reacting the same amines of general formula (X) with halogenated derivatives of general formula (XIII) according to standard methods known to a person skilled in the art.
- the amines of general formula (X) are obtained by condensation of the amines of general formula (VII) with acids of general formula (VIII) in which A, W and n are as defined previously and Gp represents a protective group of the amine function such as, for example, a carbamate group, under standard conditions of peptide synthesis as described above.
- the amine function is then deprotected (deprotection in acid medium in the case where Gp represents a carbamate group such as, for example, the tert-butoxycarbonyl group).
- amines which are not commercially available of general formula (IV) in which X represents (CH 2 ) q —, W represents H and R 19 represents an —SO 2 —NR 23 R 24 radical (hereafter designated by amines of general formula (IV) s ), can in particular be obtained in 6 stages according to methods in the literature, and in particular according to the method represented in Diagram 8 below.
- Diagram 8 the alcohol of general formula (XXI) is obtained in 3 stages from the acid of general formula (XVIII), via sulphonamide by the action of a primary or secondary amine on sulphonyl chloride under the conditions described previously for the synthesis of sulphonamides, followed by esterification, for example by a treatment with trimethylsilyldiazomethane in an alcoholic solvent such as, for example, methanol, and reduction of the ester function by a reducing agent such as LiBH 4 in a polar aprotic solvent such as, for example, THF.
- an alcoholic solvent such as, for example, methanol
- a reducing agent such as LiBH 4
- a polar aprotic solvent such as, for example, THF.
- the alcohol function is then halogenated by CBr 4 in the presence of triphenylphosphine, then converted to phthalimide by treatment of potassium phthalimidate in a polar solvent such as, for example, acetonitrile.
- a polar solvent such as, for example, acetonitrile.
- an alcoholic solvent such as, for example, ethanol
- amines of general formula (IV) in which R 19 represents the —O—P(O)(OR 26 )(OR 27 ) group (hereafter designated by amines of general formula (IV) p ) can be obtained in 2 stages according to methods in the literature, and in particular, when X represents a —(CH 2 ) q — radical, according to the method represented in Diagram 9 below.
- the phenol of general formula (XXIV) is substituted, Diagram 9, using a derivative of phosphonate type, in particular the cyanophosphonate of general formula (XXV), in the presence of a base such as, for example, triethylamine in a solvent such as dichloromethane.
- the protective group of the amine function (Gp) of the compound of formula (XXVI) is then cleaved under suitable conditions (for example in acid medium in the case where Gp is a group of carbamate type, such as the tert-butoxycarbonyl group) in order to finally produce the amine of general formula (IV) p .
- the starting reagents in which A represents the phenyl radical substituted by a alkylcarbonyloxy group are obtained from corresponding phenols by the action of a corresponding acid chloride in the presence of a base such as, for example, diisopropylethylamine in a solvent such as dichloromethane.
- the amines which are not commercially available of general formula (XXVII) or (XXVII)a in which A, B, W, R 17 , R 18 , s, t and q are as defined previously are obtained by standard methods by condensation of carboxylic acids of general formula (V) and aldehydes of general formula (VI) with linear diamines of general formula (XXIX) or cyclic diamines of general formula (XXIX)a, Diagram 11, according to methods similar to those described above and in which the protective group Gp of the amine can be a carbamate group such as the tert-butoxycarbonyl group. Cleavage of the protective group is carried out according to known methods, such as for example cleavage in hydrochloric acid medium in the case of the tert-butoxycarbonyl group.
- the amines of general formula (XXVII), Diagram 12, in which B represents —(CH 2 ) p — with p 0, X represents —(CH 2 ) q —, A, W and q are as defined previously and Gp is a protective group for an amine function (for example a protective group of carbamate type such as the tert-butoxycarbonyl group), are prepared by reacting the amines of general formula (XIV) with aldehydes of general formula (XXXI) under the conditions of reducing amination described above, or by reacting the same amines of general formula (XIV) with halogenated derivatives of general formula (XXXII) according to standard methods known to a person skilled in the art, followed by a deprotection stage of the intermediate of general formula (XXXIII) carried out under standard conditions known to a person skilled in the art.
- X represents —(CH
- the reaction mixture is extracted twice with 50 ml of CH 2 Cl 2 .
- the organic phase is washed with 10 ml of water, dried over sodium sulphate, filtered and concentrated under vacuum.
- the residue is purified on a silica column (eluent: CH 2 Cl 2 /MeOH: 97/3).
- the expected product is obtained in the form of a brown oil with a yield of 34% (0.34 g).
- 0.1 g of palladium on carbon (10%) is added to a solution of 0.84 g (2.2 mmol) of intermediate 5.1 in a mixture of ethanol (150 ml) and dichloromethane (15 ml).
- the medium is placed under a hydrogen atmosphere under a pressure of 1.5 bars for 30 minutes.
- the catalyst is filtered and the solvent is evaporated under reduced pressure.
- the free base is obtained with a yield of 71% (0.55 g; 1.56 mmol) in the form of a white solid, then placed in solution in ice-cold ethanol (45 ml) and 4.6 ml (4.7 mmol) of a 1N solution of hydrochloric acid in ether is added.
- the experimental protocol used is the same as that described for the compound of Example 2, 2-(4-nitrophenyl)ethylamine replacing N-methyl-2-(4-nitrophenyl)ethylamine and 2-hydroxy-3-methoxy-5-(dimethylamino)benzaldehyde replacing 2-hydroxy-5-(dimethylamino)benzaldehyde. A brown oil is obtained.
- the experimental protocol used is the same as that described for the compound of Example 2, 2,5-dihydroxybenzaldehyde replacing 5-(dimethylamino)-3-methoxy-2-hydroxybenzaldehyde. A brown oil is obtained.
- NMR 13 C (DMSO-d6, 100 MHz, ⁇ ): 21.4; 29.39; 32.90; 42.41; 46.19; 109.22; 111.06; 118.89; 121.59; 126.06; 126.14; 127.47; 127.57; 128.07; 129.58; 130.89; 132.15; 136.01; 140.98; 153.00; 153.67; 168.58.
- the evaporation residue is purified on a silica column (eluent: ethyl acetate/heptane: 2/1). 0.06 g (yield of 63%) of a free base is obtained.
- the hydrochloride is prepared by dissolving 0.06 g (0.14 mmol) of the previously obtained base in acetone (10 ml) and by adding 0.43 ml of a molar solution of hydrochloric acid in anhydrous diethyl ether to it.
- the phosphatase activity of the MBP-Cdc25C protein is evaluated by the dephosphorylation of 3-O-methylfluorescein-phosphate (OMFP) to 3-O-methylfluorescein (OMF) with determination of the fluorescence of the reaction product at 475 nm. This test allows identification of the inhibitors of cdc25 recombinant enzyme.
- OMFP 3-O-methylfluorescein-phosphate
- OMF 3-O-methylfluorescein
- the reaction is carried out in 384-well plate format in a final volume of 50 ⁇ l.
- the MBP-Cdc25C protein (prepared as described above) is stored in the following elution buffer: 20 mM Tris-HCl pH 7.4; 250 mM NaCl; 1 mM EDTA; 1 mM DTT; 10 mM maltose. It is diluted to a concentration of 60 ⁇ M in the following reaction buffer: 50 mM Tris-HCl pH 8.2; 50 mM NaCl; 1 mM DTT; 20% glycerol. Measurement of the background noise is carried out with the buffer without addition of the enzyme. The products are tested at decreasing concentrations starting from 80 ⁇ M.
- the reaction is initiated by the addition of an OMFP solution at 500 ⁇ M final (prepared beforehand from a 12.5 mM stock solution in 100% DMSO (Sigma #M2629)). After 4 hours at 30° C. in a disposable 384-well plate, the fluorescence measured at OD 475 nm is read using a Victor2 plate reader (EGG-Wallac). Determination of the 50% inhibitory concentration of the enzymatic reaction is calculated from three independent experiments. Only the values included in the linear part of the sigmoid are retained for linear regression analysis.
- This relates to showing that the enzymatic activity of cdc25-C phosphatase is inhibited in vivo on the purified enzyme in the presence of selected inhibitors.
- cdc25-C is inhibited, the quantity of phosphorylated cdc2 protein (inactive) increases.
- the cells of the Mia PaCa2 line are seeded at a rate of 450 000 cells in 10 cm Petri dishes in Dulbecco's modified Eagle medium completed with 10% foetal calf serum 48 hours later, the cells are treated for 1 hour with the compound to be tested or menadione at 100 ⁇ M (reference inhibitor). The medium is renewed after washing with PBS. 24 hours after the cells are scraped and lysed in the lysis buffer (Hepes 50 mM pH 7.5; NaCl 10 mM; Triton X100 1%; glycerol 10%; MgCl 2 5 mM; EDTA 1 mM; sodium orthovanadate 1 mM; protease inhibitor cocktail 1836170 Roche Diagnostics).
- the concentration of proteins is, determined in the supernatant (Bio-Rad DC Protein assay kit) and adjusted to 10 ⁇ g.
- the load buffer concentrated 5 times (TrisHCl 125 mM pH 7.4; SDS 10%; glycerol 50%; bromophenol blue 0.025%; ⁇ -mercaptoethanol 7%) is added to the samples.
- the samples are heated for 10 minutes at 100° C.
- the samples are deposited in a volume of 40 ⁇ l on Tris/Glycine 12% gels (BioRad). Migration occurs over 1 hour at 180 V.
- the proteins are transferred onto a nitrocellulose membrane (Hybond C, Amersham) under semi-dry conditions.
- the membrane is blocked for 1 hour in milk (BioRad) at 5% with 0.1% Tween 20. Then it is incubated for 6 hours with the primary antibody directed against phosphorylated cdc2 (PhosphoPlus cdc2, 91115 New England BioLabs) diluted to 1/1300 th . After washing in PBS-Tween 20 at 0.1%, the membrane is incubated for 1 hour and 30 minutes with the secondary antibody anti-rabbit Immunoglobulin G (anti-rabbit IgG-HRP, sc2030, Santa Cruz) diluted to 1/40000 th . The proteins are revealed by electrochemical luminescence (western blotting detection system ECL + , Amersham) which is detected using photographic films (BioMax light, Sigma).
- FIG. 1 represents the comparative effect of menadione and the compound of Example 1 on the phosphorylation of cdc2 in the Mia PaCa-2 line (3 hour treatment with menadione or the compound of Example 1 and sampling 24 hours later).
- the cell lines DU145 (human prostate cancer cells) and Mia-PaCa2 (human pancreatic cancer cells) were acquired from the American Tissue Culture Collection (Rockville, Md., USA).
- Dulbecco's modified Eagle medium Gibco-Brl, Cergy-Pontoise, France
- the cells were treated on day 1 for 96 hours with increasing concentrations of each of the compounds to be tested up to 50 ⁇ g/ml. At the end of this period, quantification of cell proliferation is evaluated by a colorimetric test based on the cleavage of the tetrazolium salt WST1 by mitochondrial dehydrogenases in viable cells leading to the formation of formazan (Boehringer Mannheim, Meylan, France). These tests are carried out in duplicate with 8 determinations per concentration tested. For each compound to be tested, the values included in the linear part of the sigmoid were retained for linear regression analysis and used to estimate the inhibitory concentration IC 50 . The products are solubilized in dimethylsulphoxide (DMSO) at 10 ⁇ 2 M and finally used in culture with 0.5% DMSO.
- DMSO dimethylsulphoxide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
- A subject of the present invention is new inhibitors of cdc25 phosphatases, and in particular of cdc25-C phosphatase.
- Control of the transition between the different phases of the cell cycle during mitosis or meiosis is provided by a group of proteins, the enzymatic activities of which are associated with different states of phosphorylation. These states are controlled by two large classes of enzymes: the kinases and the phosphatases.
- Synchronization of the different phases of the cell cycle thus allows reorganisation of the cell architecture at each cycle in all of the living world (microorganisms, yeasts, vertebrates, plants). Among the kinases, the cyclin-dependent kinases (CDKs) play a major role in this control of the cell cycle. Their activities are regulated by their molecular associations with other proteins called cyclins. In addition, endogenous inhibitors are capable of preventing these activities. Several inhibitors of this family of kinases are already identified and studied in several therapeutic fields such as oncology for preventing the division of tumour cells (McDonald and el-Deiry, Int. J. Oncol. (2000), 16, 871-886) or also neurobiology for preventing natural or chemically-induced apoptosis of normal cells (for example the neurones) (cf. Maas et al., J. Neurochem. (1998), 70, 1401-1410; Park et al., J. Neurosci. (1997) 17, 1256-1270).
- Moreover, the enzymatic activity of these different CDKs is controlled by two other families of enzymes which work in opposition (Jessus and Ozon, Prog. Cell cycle Res. (1995), 1, 215-228). The first groups together kinases such as Wee1 and Mik1 which deactivate the CDKs by phosphorylating certain amino acids (Den Haese et al., Mol. Biol. Cell (1995), 6, 371-385). The second groups together phosphatases such as Cdc25 which activate the CDKs by dephosphorylating tyrosine and threonine residues of CDKs (Gould et al., Science (1990), 250, 1573-1576). Dephosphorylation will be carried out in the first instance thanks to a protein/protein interaction between the cyclin and cdc25, and this complex will in the second instance target CDK (Morris and Divita, J. Mol. Biol. (1999), 286, 475-487). In addition, cyclin B is itself phosphorylated by the Cdc2 kinase (cdk1) to which it is associated (Borgne et al., J. Biol. Chem. (1999), 274, 11977-11986).
- If a single form of cdc25 is described in yeast, a family of 3 genes, cdc25-A, cdc25-B and cdc25-C, code for the human cdc25 proteins. In addition, variants originating from alternative splicing of the cdc25B gene have been identified: they are cdc25B1, cdc25B2 and cdc25B3 (Baldin et al., Oncogene (1997), 14, 2485-2495). The proteins coded by these variants would be localized differently within the cell (Davezac et al., Oncogene (2000), 19, 2179-2185). cdc25 activity is regulated by the Cdc2 and Cdk2 kinases. But in the absence of cdc2 kinase, the activity of cdc25 can be activated by other kinases (Izumi and Maller, Mol. Biol. Cell (1995), 6, 215-226). Among these, the chk1 protein phosphorylates cdc25-C on a serine in position 216, which increases its affinity for a chaperone protein 14-3-3. This bond neutralises cdc25-C and consequently maintains the cdk1 enzyme in a phosphorylated state and therefore inactive, not allowing entry into mitosis. The chaperone protein allows the complex to pass into the cytoplasm thanks to a protein unit of nuclear export (Lopez-Girona et al., Nature (1999), 397, 172-175).
- A chemical inhibitor of chk1 (SB-218070) allows a cell to continue its cell cycle despite the induction of the DNA break. This aspect allows the effectiveness of certain cytotoxic compounds such as campthotecin to be increased (Jackson et al., Cancer Res. (2000), 60, 566-572).
- The role of cdc25 phosphatases in oncogenesis was described initially by the Beach group showing that cdc25A and cdc25B by co-operating with Ha-RASG12V form foci, after transfection of normal cells (Galaktionov et al., Science (1995), 269, 1575-1577). The transforming activity of cdc25A and cdc25B is also observed when transfection is carried out in cells having a lack of the RB1 tumour suppressor gene. In addition, the expression of the cdc25-A and -B genes appears to be under the direct control of the protein coded by the c-Myc oncogene (Galaktionov et al., Nature (1996), 382, 511-517). On the other hand, cdc25-C phosphatase does not seem to be controlled by the latter.
- The overexpression of cdc25, and principally cdc25-A, appears to prevent the cell from stopping its cell cycle in the event of aggression on the genome and thus avoids a possible repair process (Mailand et al., Science (2000), 288, 1425-1429).
- Moreover, the overexpression of the different forms of cdc25 is now reported in many classifications of human tumors:
-
- Breast cancer: measurement by riboprobe shows that 32% of tumors over-express cdc25-B. The overexpression of cdc25-A is shown in nearly 50% of cancers of the breast and is associated with a poor prognosis (Cangi et al., Résumé 2984, AACR meeting San Francisco, 2000).
- Lymphomas: in the circulating lymphocytes, the expressions of the RNAs of cdc25-B1 and -B3 are detected by RT-PCR while the expressions of cdc25-A, -B2 and -C are very weak or undetectable. On the other hand, analysis of these genes in non-hodgkin's lymphomas shows a strong expression of cdc25-A and -B2 in approximately 35% of the tumors. The cdc25-B1 and -B3 variants are themselves detected in all of the tumors analysed. On the other hand, the expression of cdc25-C remains very weak in the sample group (Hernandez et al., Int. J. Cancer (2000), 89, 148-152). It is important to note the correlation between the expression of proteins such as myc and cdc25. 26 of 35 (74%) non-hodgkin's lymphomas with a raised level of cdc25-B also show an over-expression of c-myc. On the other hand, 27 out of 28 (96%) tumors with a low level of cdc25-B expression do not show any detectable c-myc (P<0.0001). This suggests that the expression of cdc25 associated with that of myc could participate in the development of this type of lymphoma (Hernandez et al., Cancer Res. (1998), 58, 1762-1767).
- Neck and head cancers: of 20 tumors examined by quantitative RT-PCR, Gasparotto et al. note that CDC25-A and -B are over-expressed whilst cdc25-C is expressed very little (Gasparotto et al., Cancer Res. (1997), 57, 2366-2368).
- Moreover, the E. Sausville group reports an inverse correlation between the level of expression of cdc25-B in a panel of 60 cell lines and their sensitivity to CDK inhibitors such as Olumucine or Flavopiridol, suggesting that the presence of cdc25 can provide resistance to certain anti-tumor agents and more particularly to CDK inhibitors (Hose et al., Proceedings of AACR, Abstract 3571, San Francisco, 2000).
- Vitamin K3, also called menadione, was the first selective inhibitor of cdc25 phosphatase described (Ham et al., Bioorg. Med. Chem. Lett. (1998) 8, 2507-2510). Other cdc25 inhibitors have since been identified and have an inhibitory activity of micromolar order on the recombinant enzymes. Among these products, the following can be noted:
- 1. Naphthoquinone analogues derived from menadione (Ham et al., Bioorg. Med. Chem. Lett. (1998) 8, 2507-2510).
- 2. Cpd5, a thioalkyl derivative of vitamin K (Tamura et al., Cancer Res. (2000), 60, 1317-1325). The inhibition constants (Kis) measured on cdc25-A, -B2 & -C are 15, 1.7 and 1.3 μmol respectively.
- 3. 4-(benzyl-(2-[(2,5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl)-2-decanoylaminobutanoic acid also called SC-alpha alpha delta 9 (Tamura et al., Oncogene (1999) 18, 6989-6996).
- 4. Certain compounds originating from a Ugi library containing groups mimicking phosphates are non-competitive inhibitors of cdc25-A which do not act on the active site. The most active compound has an IC50 of 0.5 μM and the interaction site is in the process of being identified (Bergnes et al., Bioorg. Med. Chem. Lett. (1999), 9, 2849-2854).
- 5. Quinolin-4-one and 1,7-naphthyridin-4-one derivatives. Certain compounds are inhibitors both of cdc25 and cdc2 (el-Subbagh et al., Arch. Pharm. (Weinheim.) (1999), 332, 19-24).
- 6. Dysidiolide and derivatives containing a γ-hydroxy butenolide group. The effectiveness of these products is discussed in Blanchard et al., Bioorg. Med. Chem. Lett. (1999), 9, 2537-2538.
- 7. Certain 5-substituted 2-bromoindolo[3,2-b]quinoxalines. Certain of these compounds are inhibitors of both cdc25 and cdc2 (Abadi et al., Arch. Pharm. (Weinheim.) (1998), 331, 352-358).
- The PCT Application WO 00/17190 describes amidine derivatives which inhibit the NO synthases and trap the free radicals. Because of this, these compounds present numerous pharmacological properties and their use can be envisaged in the treatment of numerous pathologies, principally in the field of neurology. A simplified general formula of these compounds could be general formula (ET1):
in which
A represents a radical which traps free radicals, for example a substituted phenyl radical;
X and Y are linking chains, for example alkylene, alkylenecarbonyl, carbonylalkylene radicals;
R represents H or alkyl; and
B represents a carbocyclic or heterocyclic aryl radical, and preferably the 2-thienyl radical. - The invention offers new inhibitors of cdc25, and in particular of cdc25-C, which correspond to general formula (I) defined below. These compounds are capable of being used as medicaments, in particular in the treatment of the following diseases/disorders:
-
- inhibition of tumorous proliferation when used alone or in combination with other treatments;
- inhibition of the proliferation of normal cells when used alone or in combination with other treatments;
- the prevention of spontaneous alopecia;
- the prevention of alopecia induced by exogenous products;
- the prevention of radiation-induced alopecia;
- the prevention of spontaneous or induced apoptosis of normal cells;
- the prevention of meiosis and fertilization;
- the prevention of oocyte maturation;
- all of the diseases/disorders corresponding to the uses mentioned for CDK inhibitors, and in particular non-tumorous proliferative diseases (for example: angiogenesis, psoriasis or the recurrence of stenosis), tumorous proliferative diseases, parasitology (proliferation of protozoa), viral infections, neurodegenerative diseases, myopathies;
- all of the diseases/disorders corresponding to clinical uses of vitamin K and its derivatives;
- Moreover, the compounds of the present invention are also, because of their properties of inhibiting cdc25 phosphatases, capable of being used to inhibit the proliferation of microorganisms, in particular yeasts. One of the advantages of these compounds is their low toxicity on healthy cells.
- At present, the Applicant has discovered in a surprising manner, that the compounds corresponding to general formula (I)
in which:
A represents an (A1) radical
in which two of the R1, R2, R3, R4 and R5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio or NR6R7 radical, it being understood moreover that: -
- either R1 and one of R2 and R4 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R2 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R4 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or also one of R1, R3 and R5 is chosen from a hydroxy, alkylcarbonyloxy and NR6R7 radical, and the B—N(W)—X—Y remainder is attached to the A radical by a nitrogen atom, R6 and R7 representing, independently each time that they occur, a hydrogen atom or an alkyl radical or R6 and R7 forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the —CR8R9—, —O—, —S— and —NR10— radicals, R8 and R9 independently representing each time that they occur a hydrogen atom or an alkyl, alkoxy, benzyloxycarbonylamino or dialkylamino radical, and R10 independently representing each time that it occurs a hydrogen atom or an alkyl radical,
or also A represents an (A2) radical
in which: - either R11 and one of R13, R14 and R15 represent hydroxy radicals whilst the other radicals among R13, R14 and R15 as well as R16 represent hydrogen atoms,
- or R12 and R16 represent hydroxy radicals whilst R11, R13, R14 and R15 represent hydrogen atoms;
B represents a —CO—, —NH—CO—(CH2)n— or —(CH2)p— radical, n being an integer from 0 to 3 and p being an integer from 0 to 1;
W represents a hydrogen atom or an alkyl radical;
X represents a —(CH2)q—, —(CH2)q—NH— or —CO—(CH2)r— radical, q being an integer from 1 to 6 and r an integer from 0 to 6;
or also the B—N(W)—X—Y group is such that it represents the
radical in which B is as defined above, t is an integer from 0 to 2, s is an integer from 0 to 1 and R17 and R18 represent radicals chosen independently from a hydrogen atom and an alkyl radical; and: - when X represents a —(CH2)q— or —CO—(CH2)r— radical, then Y represents a
radical in which R19 represents a hydrogen atom, a halogen atom, a nitro, alkyl, alkylthio, NR21R22, —SO2—NR23R24, —NH—SO2—R25 or —O—P(O)(OR26)(OR27) radical,
R21 and R22 independently representing a hydrogen atom or an alkyl radical,
R23 and R24 independently representing a hydrogen atom or an alkyl radical, or also —R23 and R24 representing together with the nitrogen atom which carries them a heterocycle with 5 to 7 members the additional members of which are chosen independently from —CHR28—, NR29—, —O— and —S—, R28 and R29 representing, independently each time that they occur, a hydrogen atom or an alkyl radical,
R25 representing an alkyl, haloalkyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals the aryl or heteroaryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, hydroxy, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals,
R26 and R27 being chosen independently from alkyl radicals,
and R20 represents a hydrogen atom, a halogen atom or an alkyl, alkoxy or alkylthio radical,
or also Y represents the (T) radical represented below
in which R20 represents a hydrogen atom or an alkyl, alkoxy or alkylthio radical, - when X represents a —(CH2)q—NH— radical or when the B—N(W)—X—Y group is such that it represents the
radical then Y exclusively represents an —SO2—R30 radical in which R30 represents an alkyl, haloalkyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals the aryl or heteroaryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, hydroxy, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals;
it being understood moreover that when the B—N(W)—X—Y group is such that it represents the
radical then B exclusively represents a —CO— or —(CH2)— radical;
or the pharmaceutically acceptable salts of compounds of general formula (I) defined above
are inhibitors of cdc25 phosphatases, and in particular inhibitors of cdc25-C phosphatase, and can therefore be used for preparing a medicament intended to inhibit cdc25 phosphatases, and in particular cdc25-C phosphatase.
- By alkyl, unless specified otherwise, is meant a linear or branched alkyl radical containing 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms and more preferentially 1 to 6 carbon atoms. By alkenyl, unless specified otherwise, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms and presenting at least one unsaturation (double bond). By alkynyl, unless specified otherwise, is meant a linear or branched alkyl radical containing 1 to 6 carbon atoms and presenting at least one double unsaturation (triple bond). By carbocyclic or heterocyclic aryl, is meant a carbocyclic or heterocyclic system comprising at least one aromatic ring, a system being said to be heterocyclic when at least one of the rings which forms it comprises a heteroatom (O, N or S); when a carbocyclic or heterocyclic aryl radical is said to be substituted unless specified otherwise, it is meant that said carbocyclic or heterocyclic aryl radical is substituted 1 to 3 times, and preferably 1 to 2 times by radicals different to a hydrogen atom which, if they are not specified, are chosen from a halogen atom and the alkyl or alkoxy radicals; moreover, unless specified otherwise, by aryl is meant a carbocyclic aryl exclusively. By haloalkyl, is meant an alkyl radical of which at least one (and optionally all) of the hydrogen atoms is replaced by a halogen atom.
- By alkylthio, alkoxy, haloalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl, aralkyl, is meant respectively the alkylthio, alkoxy, haloalkyl, haloalkoxy, aminoalkyl, alkenyl, alkynyl, aralkyl radicals the alkyl radical of which has the meaning indicated previously.
- By linear or branched alkyl having 1 to 6 carbon atoms, is meant in particular the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyl, isopentyl, hexyl, isohexyl radicals. By carbocyclic aryl, is meant in particular the phenyl and naphthyl radicals. By heterocyclic aryl or heteroaryl, is meant in particular the thienyl, imidazolyl, thiazolyl, oxazolyl and pyridyl radicals. Finally, by halogen, is meant the fluorine, chlorine, bromine or iodine atoms.
- By pharmaceutically acceptable salt, is meant in particular the addition salts with inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or with organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, pamoate, and stearate. Also included in the scope of the present invention, when they can be used, are the salts formed from bases such as sodium or potassium hydroxide. For other examples of pharmaceutically acceptable salts, reference can be made to “Salt selection for basic drugs”, Int. J. Pharm. (1986), 33, 201/217.
- In certain cases, the compounds according to the present invention can contain asymmetrical carbon atoms. As a result, the compounds according to the present invention have two possible enantiomeric forms, i.e. the “R” and “S” configurations. The present invention includes the two enantiomeric forms and all combinations of these forms, including the racemic “RS” mixtures. For the sake of simplicity, when no specific configuration is indicated in the structural formulae, it should be understood that the two enantiomeric forms and their mixtures are represented.
- Preferably, the compounds of general formula (I) according to the invention will include at least one of the following characteristics:
-
- A representing an (A1) radical
- in which two of the R1, R2, R3, R4 and R5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, alkylcarbonyloxy, hydroxy, alkoxy or NR6R7 radical, it being understood moreover that:
- either R1 and one of R2 and R4 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R2 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R4 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or also one of R1, R3 and R5 is chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical, and the B—N(W)—X—Y remainder is attached to the A radical by a nitrogen atom,
- R6 and R7 representing, independently each time that they occur, a hydrogen atom or an alkyl radical or R6 and R7 forming together with the nitrogen atom a heterocycle with 5 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the —CR8R9—, —O—, —S— and —NR10— radicals, R8 and R9 independently representing each time that they occur a hydrogen atom or an alkyl or alkoxy radical, and R10 independently representing each time that it occurs a hydrogen atom or an alkyl radical,
- or also A representing an (A2) radical
- in which:
- either R11 and one of R13, R14 and R15 represent hydroxy radicals whilst the other radicals among R13, R14 and R15 as well as R16 represent hydrogen atoms,
- or R12 and R16 represent hydroxy radicals whilst R11, R13, R14 and R15 represent hydrogen atoms;
- B representing a —CO—, —NH—CO—(CH2)n— or —(CH2)p— radical, n being an integer from 0 to 2 and p being an integer from 0 to 1;
- W representing a hydrogen atom or an alkyl radical;
- X representing a —(CH2)q—, —(CH2)q—NH— or —CO—(CH2)r radical, q being an integer from 1 to 4 and r an integer from 0 to 5;
- or also the B—N(W)—X—Y group being such that it represents the
- radical in which B is as defined in general formula (I), t is an integer from 0 to 2, s is an integer from 0 to 1, R17 and R18 represent radicals chosen independently from a hydrogen atom and an alkyl radical;
- when X represents a —(CH2)q— or —CO—(CH2)r— radical, Y representing a
- radical in which R19 represents a hydrogen atom, a halogen atom, a nitro, alkyl, alkylthio, NR21R22, —SO2—NR23R24, —NH—SO2—R25 or —O—P(O)(OR26)(OR27) radical, R21 and R22 independently representing a hydrogen atom or an alkyl radical, R23 and R24 independently representing a hydrogen atom or an alkyl radical, or R23 and R24 representing together with the nitrogen atom which carries them a heterocycle with 5 to 6 members the additional members of which are chosen independently from —CHR28—, —NR29—, —O— and —S—, R28 and R29 representing, independently each time that they occur, a hydrogen atom or an alkyl radical, R25 representing an alkyl or aryl radical optionally substituted by one or more radicals chosen from a halogen atom and alkyl, haloalkyl, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals,
- R26 and R27 being chosen independently from alkyl radicals,
- and R20 represents a hydrogen atom or an alkyl or alkoxy radical,
- or also Y representing the radical of formula (T)
- in which R20 represents a hydrogen atom or an alkyl or alkoxy radical;
- when X represents a —(CH2)q—NH— radical or when the B—N(W)—X—Y group is such that it represents the
- radical Y representing an —SO2—R30 radical in which R30 represents an alkyl, haloalkyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals the aryl or heteroaryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals.
- A representing an (A1) radical
- More preferentially, the compounds of general formula (I) according to the invention will include at least one of the following characteristics:
-
- A representing an (A1) radical
- in which two of the R1, R2, R3, R4 and R5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, alkylcarbonyloxy, hydroxy, alkoxy or NR6R7 radical, it being understood moreover that:
- either R1 and one of R2 and R4 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R2 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R4 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or also one of R1, R3 and R5 is chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical, and the B—N(W)—X—Y remainder is attached to the A radical by a nitrogen atom,
- R6 and R7 representing, independently each time that they occur, a hydrogen atom or an alkyl radical containing 1 to 3 carbon atoms or R6 and R7 forming together with the nitrogen atom a heterocycle with 5 to 6 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the —CR8R9—, —O— and —NR10— radicals, R8 and R9 independently representing each time that they occur a hydrogen atom or an alkyl or alkoxy radical, and R10 independently representing each time that it occurs a hydrogen atom or an alkyl radical,
- or also A representing an (A2) radical
- in which:
- either R11 and R15 represent hydroxy radicals whilst R12, R13, R14 and R16 represent hydrogen atoms,
- or R12 and R16 represent hydroxy radicals whilst R11, R13, R14 and R15 represent hydrogen atoms;
- W representing a hydrogen atom or a methyl or ethyl radical;
- X representing a —(CH2)q—, —(CH2)q—NH— or —CO—(CH2)r radical, q being an integer from 1 to 3 and r an integer from 0 to 4;
- or also the B—N(W)—X—Y group being such that it represents the
- radical in which B is as defined in general formula (I), t is an integer from 0 to 2, s is an integer from 0 to 1, R17 and R18 represent radicals chosen independently from a hydrogen atom and an alkyl radical containing 1 to 3 carbon atoms;
- when X represents a —(CH2)q— or —CO—(CH2)r— radical, Y representing a
- radical in which R19 represents a nitro, NR21R22, —SO2—NR23R24, —NH—SO2—R25 or —O—P(O)(OR26)(OR27) radical,
- R21 and R22 independently representing a hydrogen atom or an alkyl radical,
- R23 and R24 independently representing a hydrogen atom or an alkyl radical, or R23 and R24 representing together with the nitrogen atom which carries them a heterocycle with 5 to 6 members the additional members of which are chosen independently from —CHR28—, —NR29—, —O— and —S—, R28 and R29 representing, independently each time that they occur, a hydrogen atom or an alkyl radical,
- R25 representing an alkyl or aryl radical optionally substituted by one or more radicals chosen from a halogen atom and alkyl, haloalkyl, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals,
- R26 and R27 being chosen independently from alkyl radicals,
- and R20 represents a hydrogen atom or an alkyl radical,
- or also Y representing the radical of formula (T)
- in which R20 represents a hydrogen atom or an alkyl radical;
- when X represents a —(CH2)q—NH— radical or when the B—N(W)—X—Y group is such that it represents the
- radical, Y representing an —SO2—R30 radical in which R30 represents an alkyl, haloalkyl radical or one of the aryl or aralkyl radicals the aryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals.
- A representing an (A1) radical
- Yet more preferentially, the compounds of general formula (I) according to the invention will include at least one of the following characteristics:
-
- A representing an (A1) radical
- in which two of the R1, R2, R3, R4 and R5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, acetoxy, hydroxy, methoxy or NR6R7 radical, it being understood moreover that:
- either R1 and one of R2 and R4 are chosen independently from a hydroxy, acetoxy and NR6R7 radical,
- or R2 and one of R3 and R5 are chosen independently from a hydroxy, acetoxy and NR6R7 radical,
- or R4 and one of R3 and R5 are chosen independently from a hydroxy, acetoxy and NR6R7 radical,
- or also one of R1, R3 and R5 is chosen independently from a hydroxy, acetoxy and NR6R7 radical, and the B—N(W)—X—Y remainder is attached to the A radical by a nitrogen atom,
- R6 and R7 representing, independently each time that they occur, a hydrogen atom or an alkyl radical containing 1 to 3 carbon atoms (this alkyl radical preferably being the methyl radical) or R6 and R7 forming together with the nitrogen atom a heterocycle containing 6 members and comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the —CR8R9—, —O— and —NR10— radicals, R8 and R9 independently representing each time that they occur a hydrogen atom or an alkyl radical (this alkyl radical preferably being the methyl radical), and R10 independently representing each time that it occurs a hydrogen atom or an alkyl radical (this alkyl radical preferably being the methyl radical),
- or also A representing an (A2) radical
- in which R11 and R15 represent hydroxy radicals whilst R12, R13, R14 and R16 represent hydrogen atoms;
- W representing a hydrogen atom or a methyl radical;
- X representing a —(CH2)q—, —(CH2)q—NH— or —CO—(CH2)r radical, q being an integer from 1 to 3 and r an integer from 0 to 4;
- or also the B—N(W)—X—Y group being such that it represents the
- radical in which B is as defined in general formula (I), t is an integer from 0 to 2, s is an integer from 0 to 1, R17 and R18 represent radicals chosen independently from a hydrogen atom and a methyl radical;
- when X represents a —(CH2)q— or —CO—(CH2)r— radical, Y representing a
- radical in which R19 represents a nitro, NR21R22, —SO2—NR23R24, —NH—SO2—R25 or —O—P(O)(OR26)(OR27) radical,
- R21 and R22 independently representing a hydrogen atom or an alkyl radical,
- R23 and R24 independently representing a hydrogen atom or an alkyl radical, or R23 and R24 representing together with the nitrogen atom which carries them a heterocycle with 5 to 6 members the additional members of which are chosen independently from —CHR28—, —NR29—, —O— and —S—, R28 and R29 representing, independently each time that they occur, a hydrogen atom or an alkyl radical,
- R25 representing an alkyl or aryl radical optionally substituted by one or more radicals chosen from a halogen atom and alkyl, haloalkyl, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals,
- R26 and R27 being chosen independently from alkyl radicals,
- and R20 represents a hydrogen atom or a methyl radical (and preferably a hydrogen atom),
- or also Y representing the radical of formula (T)
- in which R20 represents a hydrogen atom or a methyl radical (and preferably a hydrogen atom);
- when X represents a —(CH2)q—NH— radical or when the B—N(W)—X—Y group is such that it represents the
- radical Y representing an —SO2—R30 radical in which R30 represents an alkyl radical or one of the aryl or aralkyl radicals the aryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are methyl radicals.
- A representing an (A1) radical
- For a use according to the invention, the following compounds described (if appropriate in the form of salts) in the examples will be particularly preferred:
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-phenol;
- 4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2,7-dihydroxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl}-2-napthalenecarboxamide;
- 3-[(3-{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-[4-(dimethylamino)phenyl]propanamide;
- 4-(4-aminophenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]butanamide;
- 4-(dimethylamino)-2-methoxy-6-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(dimethylamino)-2-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-(dimethylamino)-6-methoxy-4-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-1,4-benzenediol;
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenyl acetate;
- 3,7-dihydroxy-N-[2-(4-nitrophenyl)ethyl]-2-naphthamide;
- N-[4-(dimethylamino)benzyl]-3,7-dihydroxy-2-naphthamide;
- diethyl 4-{2-[(3,7-dihydroxy-2-naphthoyl)amino]ethyl}phenylphosphate;
- N-{2-[4-(aminosulphonyl)phenyl]ethyl}-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-aminophenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(methylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- N-(2-{4-[(butylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methylphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(1-naphthylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[2-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- N-(2-{4-[(benzylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[3-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-nitrophenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[4-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(thien-2-ylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methoxyphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(1-methyl-1H-imidazol-4-yl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- N-[2-(4-{[(4-fluorophenyl)sulphonyl]amino}phenyl)ethyl]-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{3-[(4-methyl-1-piperidinyl)sulphonyl]benzyl}-2-naphthamide;
- 5-(4-{[(1E)-amino(2-thienyl)methylidene]amino}phenyl)-N-[2-(dimethylamino) phenyl]pentanamide;
- 3-({4-[(4-methylphenyl)sulphonyl]piperazin-1-yl}carbonyl)naphthalene-2,6-diol;
- 3-{[4-(methylsulphonyl)piperazin-1-yl]carbonyl}naphthalene-2,6-diol;
- 3-{[4-(butylsulphonyl)piperazin-1-yl]carbonyl}naphthalene-2,6-diol;
or the pharmaceutically acceptable salts of such compounds. - The following compounds will quite particularly be preferred for a use according to the invention:
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-phenol;
- 4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-(dimethylamino)-6-methoxy-4-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-1,4-benzenediol;
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenyl acetate;
- diethyl 4-{2-[(3,7-dihydroxy-2-naphthoyl)amino]ethyl}phenylphosphate;
- N-{2-[4-(aminosulphonyl)phenyl]ethyl}-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(methylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- N-(2-{4-[(butylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methylphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[3-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- N-[2-(4-{[(4-fluorophenyl)sulphonyl]amino}phenyl)ethyl]-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{3-[(4-methyl-1-piperidinyl)sulphonyl]benzyl}-2-naphthamide;
- 3-({4-[(4-methylphenyl)sulphonyl]piperazin-1-yl}carbonyl)naphthalene-2,6-diol;
or the pharmaceutically acceptable salts of such compounds. - Moreover, 5-(4-{[(1E)-amino(2-thienyl)methylidene]amino}phenyl)-N-[2-(dimethylamino)phenyl]pentanamide and its pharmaceutically acceptable salts are also preferred for a use according to the invention.
- The following compounds will be quite particularly preferred for a use according to the invention:
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-phenol;
- 4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-1,4-benzenediol;
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenyl acetate;
- 3,7-dihydroxy-N-{2-[4-({[3-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-{3-[(4-methyl-1-piperidinyl)sulphonyl]benzyl}-2-naphthamide;
or the pharmaceutically acceptable salts of such compounds. - Preferably, the compounds of general formula (I) will be used to prepare a medicament intended to treat a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products and radiation-induced alopecia.
- Preferably however, the compounds of general formula (I) used for preparing a medicament intended to treat proliferative diseases, parasitic diseases and viral infections are such that the Y radical does not represent the radical of formula (T). The compounds of general formula (I) in which the Y radical represents the radical of formula (T) will therefore be preferably used for preparing a medicament intended to treat spontaneous alopecia, alopecia induced by exogenous products, and radiation-induced alopecia
- Quite particularly, the compounds of general formula (I) could be used for preparing a medicament intended to treat cancer, and in particular cancer of the breast, lymphomas, cancers of the neck and head, cancer of the lung, cancer of the colon, cancer of the prostate and cancer of the pancreas.
- According to a particular variant of the invention, the compounds of general formula (I) as defined above can be used for preparing a medicament intended to treat spontaneous alopecia, alopecia induced by exogenous products or radiation-induced alopecia.
- The present invention also offers, as medicaments, the compounds of general formula (II)
in which
A represents an (A1) radical
in which two of the R1, R2, R3, R4 and R5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio or NR6R7 radical, it being understood moreover that: -
- either R1 and one of R2 and R4 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R2 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R4 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or also one of R1, R3 and R5 is chosen from a hydroxy, alkylcarbonyloxy and NR6R7 radical, and the B—N(W)—X—Y remainder is attached to the A radical by a nitrogen atom, R6 and R7 representing, independently each time that they occur, a hydrogen atom or an alkyl radical or R6 and R7 forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the —CR8R9—, —O—, —S— and —NR10— radicals, R8 and R9 independently representing each time that they occur a hydrogen atom or an alkyl, alkoxy, benzyloxycarbonylamino or dialkylamino radical, and R10 independently representing each time that it occurs a hydrogen atom or an alkyl radical,
or also A represents an (A2) radical
in which: - either R11 and one of R13, R14 and R15 represent hydroxy radicals whilst the other radicals from R13, R14 and R15 as well as R16 represent hydrogen atoms,
- or R12 and R16 represent hydroxy radicals whilst R11, R13, R14 and R15 represent hydrogen atoms;
B represents a —CO—, —NH—CO—(CH2)n— or —(CH2)p— radical, n being an integer from 0 to 3 and p being an integer from 0 to 1;
W represents a hydrogen atom or an alkyl radical;
X represents a —(CH2)q—, —(CH2)q—NH— or —CO—(CH2)r— radical, q being an integer from 1 to 6 and r an integer from 0 to 6;
or also the B—N(W)—X—Y group is such that it represents the
radical in which B is as defined above, t is an integer from 0 to 2, s is an integer from 0 to 1 and R17 and R18 represent radicals chosen independently from a hydrogen atom and an alkyl radical; and: - when X represents a —(CH2)q— or —CO—(CH2)r— radical, then Y represents a
radical in which R19 represents a hydrogen atom, a halogen atom, a nitro, alkyl, alkylthio, NR21R22, —SO2—NR23R24, —NH—SO2—R25 or —O—P(O)(OR26)(OR27) radical,
R21 and R22 independently representing a hydrogen atom or an alkyl radical,
R23 and R24 independently representing a hydrogen atom or an alkyl radical, or R23 and R24 representing together with the nitrogen atom which carries them a heterocycle with 5 to 7 members the additional members of which are chosen independently from —CHR28—, —NR29—, —O— and —S—, R28 and R29 representing, independently each time that they occur, a hydrogen atom or an alkyl radical,
R25 representing an alkyl, haloalkyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals the aryl or heteroaryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, hydroxy, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals,
R26 and R27 being chosen independently from alkyl radicals,
and R20 represents a hydrogen atom, a halogen atom or an alkyl, alkoxy or alkylthio radical; - when X represents a —(CH2)q—NH— radical or when the B—N(W)—X—Y group is such that it represents the
radical then Y exclusively represents an —SO2—R30 radical in which R30 represents an alkyl, haloalkyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals the aryl or heteroaryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, hydroxy, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals;
it being understood moreover that when the B—N(W)—X—Y group is such that it represents the
radical then B exclusively represents a —CO— or —(CH2)— radical;
or the pharmaceutically acceptable salts of compounds of general formula (II).
- In particular, the invention relates, as medicaments, to the following compounds of general formula (II):
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(4-aminophenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]butanamide;
- 4-(dimethylamino)-2-methoxy-6-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(dimethylamino)-2-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-(dimethylamino)-6-methoxy-4-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-1,4-benzenediol;
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenyl acetate;
- 3,7-dihydroxy-N-[2-(4-nitrophenyl)ethyl]-2-naphthamide;
- N-[4-(dimethylamino)benzyl]-3,7-dihydroxy-2-naphthamide;
- diethyl 4-{2-[(3,7-dihydroxy-2-naphthoyl)amino]ethyl}phenylphosphate;
- N-{2-[4-(aminosulphonyl)phenyl]ethyl}-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-aminophenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(methylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- N-(2-{4-[(butylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methylphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(1-naphthylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[2-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- N-(2-{4-[(benzylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[3-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-nitrophenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[4-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(thien-2-ylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methoxyphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(1-methyl-1H-imidazol-4-yl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- N-[2-(4-{[(4-fluorophenyl)sulphonyl]amino}phenyl)ethyl]-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{3-[(4-methyl-1-piperidinyl)sulphonyl]benzyl}-2-naphthamide;
- 3-({4-[(4-methylphenyl)sulphonyl]piperazin-1-yl}carbonyl)naphthalene-2,6-diol;
- 3-{[4-(methylsulphonyl)piperazin-1-yl]carbonyl}naphthalene-2,6-diol;
- 3-{[4-(butylsulphonyl)piperazin-1-yl]carbonyl}naphthalene-2,6-diol;
and their pharmaceutically acceptable salts. - Moreover, the invention also relates to 5-(4-{[(1E)-amino (2-thienyl)methylidene]amino}phenyl)-N-[2-(dimethylamino)phenyl]pentanamide or one of its pharmaceutically acceptable salts, as a medicament.
- In addition, the invention relates to the pharmaceutical compositions comprising, as active ingredient, at least one of the compounds of general formula (II) defined above or a pharmaceutically acceptable salt of such a compound, and preferably a compound chosen from the following compounds:
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(4-aminophenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]butanamide;
- 4-(dimethylamino)-2-methoxy-6-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(dimethylamino)-2-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-(dimethylamino)-6-methoxy-4-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-1,4-benzenediol;
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenyl acetate;
- 3,7-dihydroxy-N-[2-(4-nitrophenyl)ethyl]-2-naphthamide;
- N-[4-(dimethylamino)benzyl]-3,7-dihydroxy-2-naphthamide;
- diethyl 4-{2-[(3,7-dihydroxy-2-naphthoyl)amino]ethyl}phenylphosphate;
- N-{2-[4-(aminosulphonyl)phenyl]ethyl}-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-aminophenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(methylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- N-(2-{4-[(butylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methylphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(1-naphthylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[2-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- N-(2-{4-[(benzylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[3-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-nitrophenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[4-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(thien-2-ylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methoxyphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(1-methyl-1H-imidazol-4-yl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- N-[2-(4-{[(4-fluorophenyl)sulphonyl]amino}phenyl)ethyl]-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{3-[(4-methyl-1-piperidinyl)sulphonyl]benzyl}-2-naphthamide;
- 3-({4-[(4-methylphenyl)sulphonyl]piperazin-1-yl}carbonyl)naphthalene-2,6-diol;
- 3-{[4-(methylsulphonyl)piperazin-1-yl]carbonyl}naphthalene-2,6-diol;
- 3-{[4-(butylsulphonyl)piperazin-1-yl]carbonyl}naphthalene-2,6-diol;
and their pharmaceutically acceptable salts. - According to a variant of the invention, a pharmaceutical composition according to the invention will include 5-(4-{[(1E)-amino(2-thienyl)methylidene]amino}phenyl)-N-[2-(dimethylamino)phenyl]pentanamide or one of its pharmaceutically acceptable salts.
- More preferentially, a pharmaceutical composition according to the invention will include, as active ingredient, a compound chosen from the following compounds:
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-phenol;
- 4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-(dimethylamino)-6-methoxy-4-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl-1,4-benzenediol;
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenyl acetate;
- diethyl 4-{2-[(3,7-dihydroxy-2-naphthoyl)amino]ethyl}phenylphosphate;
- N-{2-[4-(aminosulphonyl)phenyl]ethyl}-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(methylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- N-(2-{4-[(butylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methylphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[3-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- N-[2-(4-{[(4-fluorophenyl)sulphonyl]amino}phenyl)ethyl]-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{3-[(4-methyl-1-piperidinyl)sulphonyl]benzyl}-2-naphthamide;
- 3-({4-[(4-methylphenyl)sulphonyl]piperazin-1-yl}carbonyl)naphthalene-2,6-diol;
or a pharmaceutically acceptable salt of one of the latter. - Also more preferentially, a pharmaceutical composition according to the invention will include, as active ingredient, a compound chosen from the following compounds:
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-phenol;
- 4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-1,4-benzenediol;
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenyl acetate;
- 3,7-dihydroxy-N-{2-[4-({[3-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-{3-[(4-methyl-1-piperidinyl)sulphonyl]benzyl}-2-naphthamide;
or a pharmaceutically acceptable salt of one of the latter. - The invention relates moreover to the use of a compound of general formula (II) as defined previously for preparing a medicament intended to treat a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, neurodegenerative diseases, myopathies, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia
- Preferably, the compounds of general formula (II) will be used for preparing a medicament intended to treat a disease chosen from the following diseases: tumorous proliferative diseases and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products and radiation-induced alopecia.
- Quite particularly, the compounds of general formula (II) could be used for preparing a medicament intended to treat cancer, and in particular cancer of the breast, lymphomas, cancers of the neck and head, cancer of the lung, cancer of the colon, cancer of the prostate and cancer of the pancreas.
- The invention also relates, as new industrial products, to the compounds of general formula (III)
in which
A represents an (A1) radical
in which two of the R1, R2, R3, R4 and R5 groups represent hydrogen atoms and the other three are chosen independently from a hydrogen atom, a halogen atom and an alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio or NR6R7 radical, it being understood moreover that: -
- either R1 and one of R2 and R4 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R2 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or R4 and one of R3 and R5 are chosen independently from a hydroxy, alkylcarbonyloxy and NR6R7 radical,
- or also one of R1, R3 and R5 is chosen from a hydroxy, alkylcarbonyloxy and NR6R7 radical, and the B—N(W)—X—Y remainder is attached to the A radical by a nitrogen atom, R6 and R7 representing, independently each time that they occur, a hydrogen atom or an alkyl radical or R6 and R7 forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the —CR8R9—, —O—, —S— and —NR10— radicals, R8 and R9 independently representing each time that they occur a hydrogen atom or an alkyl, alkoxy, benzyloxycarbonylamino or dialkylamino radical, and R10 independently representing each time that it occurs a hydrogen atom or an alkyl radical,
or also A represents an (A2) radical
in which: - either R11 and one of R13, R14 and R15 represent hydroxy radicals whilst the other radicals from R13, R14 and R15 as well as R16 represent hydrogen atoms,
- or R12 and R16 represent hydroxy radicals whilst R11, R13, R14 and R15 represent hydrogen atoms;
B represents a —CO—, —NH—CO—(CH2)n— or —(CH2)p— radical, n being an integer from 0 to 3 and p being an integer from 0 to 1;
W represents a hydrogen atom or an alkyl radical;
X represents a —(CH2)q—, —(CH2)q—NH— or —CO—(CH2)r— radical, q being an integer from 1 to 6 and r an integer from 0 to 6;
or also the B—N(W)—X—Y group is such that it represents the
radical in which B is as defined above, t is an integer from 0 to 2, s is an integer from 0 to 1 and R17 and R18 represent radicals chosen independently from a hydrogen atom and an alkyl radical; and: - when X represents a —(CH2)q— or —CO—(CH2)r— radical, then Y represents a
radical in which R19 represents an —SO2—NR23R24, —NH—SO2—R25 or —O—P(O)(OR26)(OR27) radical,
R23 and R24 independently representing a hydrogen atom or an alkyl radical, or R23 and R24 representing together with the nitrogen atom which carries them a heterocycle with 5 to 7 members the additional members of which are chosen independently from —CHR28—, —NR29—, —O— and —S—, R28 and R29 representing, independently each time that they occur, a hydrogen atom or an alkyl radical,
R25 representing an alkyl, haloalkyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals the aryl or heteroaryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, hydroxy, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals,
R26 and R27 being chosen independently from alkyl radicals,
and R20 represents a hydrogen atom, a halogen atom or an alkyl, alkoxy or alkylthio radical; - when X represents a —(CH2)q—NH— radical or when the B—N(W)—X—Y group is such that it represents the
radical then Y exclusively represents an —SO2—R30 radical in which R30 represents an alkyl, haloalkyl radical or one of the aryl, heteroaryl, aralkyl or heteroaralkyl radicals the aryl or heteroaryl nucleus of which is optionally substituted by one or more radicals chosen independently from a halogen atom and alkyl, haloalkyl, hydroxy, alkoxy or nitro radicals, except for the optional nitrogen atoms of the heteroaryl nucleus for which the optional substituents are chosen from alkyl radicals;
it being understood moreover that when the B—N(W)—X—Y group is such that it represents the
radical then B exclusively represents a —CO— or —(CH2)— radical;
or the salts of compounds of general formula (III).
- In particular, the invention relates, as new products, to the following compounds of general formula (III):
- diethyl 4-{2-[(3,7-dihydroxy-2-naphthoyl)amino]ethyl}phenylphosphate;
- N-{2-[4-(aminosulphonyl)phenyl]ethyl}-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(methylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- N-(2-{4-[(butylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methylphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(1-naphthylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[2-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- N-(2-{4-[(benzylsulphonyl)amino]phenyl}ethyl)-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[3-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-nitrophenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-{2-[4-({[4-(trifluoromethyl)phenyl]sulphonyl}amino)phenyl]ethyl}-2-naphthamide;
- 3,7-dihydroxy-N-(2-{4-[(thien-2-ylsulphonyl)amino]phenyl}ethyl)-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(4-methoxyphenyl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- 3,7-dihydroxy-N-[2-(4-{[(1-methyl-1H-imidazol-4-yl)sulphonyl]amino}phenyl)ethyl]-2-naphthamide;
- N-[2-(4-{[(4-fluorophenyl)sulphonyl]amino}phenyl)ethyl]-3,7-dihydroxy-2-naphthamide;
- 3,7-dihydroxy-N-{3-[(4-methyl-1-piperidinyl)sulphonyl]benzyl}-2-naphthamide;
- 3-({4-[(4-methylphenyl)sulphonyl]piperazin-1-yl}carbonyl)naphthalene-2,6-diol;
- 3-{[4-(methylsulphonyl)piperazin-1-yl]carbonyl}naphthalene-2,6-diol;
- 3-{[4-(butylsulphonyl)piperazin-1-yl]carbonyl}naphthalene-2,6-diol;
and the salts of the latter. - The invention also relates, as new products, to the following compounds of general formula (I):
- 4-(dimethylamino)-2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(4-aminophenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]butanamide;
- 4-(dimethylamino)-2-methoxy-6-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 4-(dimethylamino)-2-({[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-(dimethylamino)-6-methoxy-4-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol;
- 2-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)-1,4-benzenediol;
- 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenyl acetate;
- 3,7-dihydroxy-N-[2-(4-nitrophenyl)ethyl]-2-naphthamide;
- N-[4-(dimethylamino)benzyl]-3,7-dihydroxy-2-naphthamide;
and the salts of the latter. - The invention also relates, as a new industrial product corresponding to general formula (I), to 5-(4-{[(1E)-amino(2-thienyl)methylidene]amino}phenyl)-N-[2-(dimethylamino)phenyl]pentanamide.
- The invention also relates to pharmaceutical compositions comprising, as active ingredient, a compound of general formula (III) or a pharmaceutically acceptable salt of the latter.
- Another subject of the invention is the use of compounds of general formula (III) or of pharmaceutically acceptable salts of the latter for preparing medicaments intended to treat a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, neurodegenerative diseases, myopathies; spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia
- Preferably, the compounds of general formula (III) are used for preparing a medicament intended to treat a disease chosen from the following diseases: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia
- Quite particularly, the compounds of general formula (III) could be used for preparing a medicament intended to treat cancer, and in particular cancer of the breast, lymphomas, cancers of the neck and head, cancer of the lung, cancer of the colon, cancer of the prostate and cancer of the pancreas.
- Generally, the same preferences as those indicated for the compounds of general formula (I) are moreover applicable by analogy to the compounds of general formulae (II) and (III).
- The invention also relates to a process for the preparation of a compound of general formula (I).3
in which A, B, W, X, R20 and R25 have the same meaning as in general formula (I), said process being characterized in that the compound of general formula (I).2
is reacted with a compound of general formula R25—SO2Cl in an aprotic solvent (such as tetrahydrofuran, dichloromethane or dimethylformamide) and in the presence of a base (such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base being able if appropriate to also serve as reaction solvent). - The invention also relates to a process for the preparation of a compound of general formula (I).7
in which A, B, W, q and R30 have the same meaning as in general formula (I),
said process being characterized in that the compound of formula (XXVII)
is reacted with a compound of general formula
R30—SO2Cl (XXVIII)
in an aprotic solvent (such as tetrahydrofuran, dichloromethane or dimethylformamide) and in the presence of a base (such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base being able if appropriate to also serve as reaction solvent). - The invention also relates to a process for the preparation of a compound of general formula (I).8
in which A, B, R17, R18, s, t and R30 have the same meaning as in general formula (I), said process being characterized in that the compound of formula (XXVII)a
is reacted with a compound of general formula
R30—SO2Cl (XXVIII)
in an aprotic solvent (such as tetrahydrofuran, dichloromethane or dimethylformamide) and in the presence of a base (such as pyridine, triethylamine or a supported base, for example morpholinomethyl polystyrene resin; the base being able if appropriate to also serve as reaction solvent). - The invention also relates to a process for the preparation of a compound of general formula (I).9
in which A, W, X, R20, R26 and R27 have the same meaning as in general formula (I), and B represents the —CO— or —CH2— radical,
said process being characterized in that the amine of general formula (IV)p
is reacted with: -
- either, when B represents the —CO— radical, with an acid of general formula
A-CO2H (V)
in an aprotic solvent (such as tetrahydrofuran, dichloromethane or dimethylformamide) and in the presence of a peptide coupling agent (such as dicyclohexylcarbodiimide (DCC), 1,1′-carbonyldiimidazole (CDI) or 1-(3-dimethylaminoproyl)-3-ethylcarbodiimide)hydrochloride; - or, when B represents the —CH2— radical, with an aldehyde of general formula
A-CHO (VI)
in an alcoholic solvent (such as, for example, methanol) and in the presence of a reducing agent (such as NaBH4, NaBH3CN or also a resin containing borohydride ions).
- either, when B represents the —CO— radical, with an acid of general formula
- The pharmaceutical composition can be in the form of a solid, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories. Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.
- The pharmaceutical compositions containing a compound of the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups. Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.
- The administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by intramuscular injection, etc.
- The administration dose envisaged for a medicament according to the invention is comprised between 0.1 mg and 10 g according to the type of active compound used.
- In accordance with the invention, the compounds of general formula (I) can be prepared for example by the processes described below.
- Preparation of the Compounds of the Invention
- The preparation processes below are given by way of illustration and a person skilled in the art will be able to subject them to the variations that he judges useful, both as regards to the reagents and the conditions and techniques of the reactions.
- A) Case where Y Represents a Substituted Phenyl Radical
- 1. Case where Y Represents a Radical of Nitrophenyl Type:
- The compounds of general formula (I) in which Y represents a radical of nitrophenyl type (hereafter designated by <<compounds of general sub-formula (I).1>>) can be easily prepared according to identical or similar procedures to those described in the PCT Patent Application WO 00/17190.
- 2. Case where Y Represents a Radical of Aminophenyl, Dialkylaminophenyl or, Alkylsulphonylamino Type or Also a Radical of Formula (T):
- In the case where Y represents a radical of aminophenyl, dialkylaminophenyl, alkylsulphonylamino type or also the radical of formula (T), the compounds of general formula (I) can be prepared from nitrophenyl derivatives of general sub-formula (I).1 according to the procedures represented in Diagram 1 below.
- In the case where neither X or B represents —CH2—, the derivatives of aminophenyl type of general sub-formula (I).2, in which A, B, W, X and R20 are as defined above can be easily obtained, Diagram 1, by reduction of the compounds of general formula (I).1, for example, by the action of hydrogen in the presence of a catalyst of the palladium on carbon type in a solvent such as for example methanol, ethanol, dichloromethane or tetrahydrofuran (THF). In the particular case where at least one of X and B represents —CH2—, the reduction of the nitro function can be carried out, for example, by heating the product in an appropriate solvent such as ethyl acetate with a little ethanol in the presence of SnCl2 (J. Heterocyclic Chem. (1987), 24, 927-930; Tetrahedron Letters (1984), 25(8), 839-842) or in the presence of SnCl2/Zn (Synthesis. (1996), 9, 1076-1078), using NaBH4—BiCl3 (Synth. Comm. (1995), 25(23), 3799-3803) in a solvent such as ethanol, or then by using Raney Ni with added hydrazine hydrate (Monatshefte für Chemie, (1995), 126, 725-732), or also by using indium in a mixture of ethanol and ammonium chloride under reflux (Synlett (1998), 9, 1028).
- The compounds of general formula (I) in which Y represents the alkylsulphonylaminophenyl radical (i.e. the compounds of general sub-formula (I).3) can be easily prepared from the compounds of general formula (I).2, Diagram 1, according to standard methods of sulphonamide synthesis, by the action of a sulphonyl halide on an aminated derivative, in an aprotic solvent such as THF, dichloromethane or dimethylformamide (DMF), in the presence of a base such as pyridine, triethylamine or a supported base such as morpholinomethyl polystyrene resin or also by using pyridine as solvent.
- The compounds of general formula (I) in which Y represents the (T) radical (i.e. the compounds of general sub-formula (I).4) can be easily prepared from the compounds of general formula (I).2, Diagram 1, according to identical or similar procedures to those described in the PCT Patent Application WO 00/17190.
- Finally, the derivatives of alkylaminophenyl or dialkylaminophenyl type (the compounds of sub-general formulae (I).5 and (I).6 respectively represented in Diagram 1) can be obtained by mono- or dialkylation of the aminophenyl derivatives of general sub-formula (I).2 according to standard methods known to a person skilled in the art. Mono-alkylation is carried out by reducing amination with an aldehyde or by nucleophilic substitution by reacting with an R21-Hal halogenoalkyl equivalent in order to produce the monoalkylated derivative of general sub-formula (I).5. A second alkylation can then be carried out if appropriate by means of an R22-Hal halogenoalkyl in order to produce the dialkylated derivative of general sub-formula (I).6.
- In the particular case where R21=R22=—CH3 and where neither X or B represents —CH2—, the nitrophenyl derivative of general sub-formula (I).2 can be treated with suitable quantities of paraformaldehyde under a hydrogen atmosphere in a solvent such as ethanol and in the presence of a catalyst of the palladium on carbon type, in order to produce the dimethylaminophenyl derivative of general sub-formula (I).6a (cf. Diagram 2 below).
3. Other Cases where Y Represents a Radical of the Substituted Phenyl Type: - In the other cases not yet mentioned where Y represents a radical of the substituted phenyl type, the preparation of the compounds of general formula (I) will be carried out in a standard manner known to a person skilled in the art.
-
- The carboxamides of general formula (I), Diagram 3, in which B represents —CO— and A, W, X, R19 and R20 are as defined previously, are prepared by condensation of the acids of general formula (V), with the amines of general formula (IV) under standard conditions of peptide synthesis (M. Bodanszky, The Practice of Peptide Synthesis, 145 (Springer-Verlag, 1984)), for example in THF, dichloromethane or DMF in the presence of a coupling reagent such as dicyclohexylcarbodiimide (DCC), 1,1′-carbonyldiimidazole (CDI) (J. Med. Chem. (1992), 35 (23), 4464-4472) or 1-(3-dimethylaminoproyl)-3-ethylcarbodiimide hydrochloride (EDC or WSCI) (John Jones, The chemical synthesis of peptides, 54 (Clarendon Press, Oxford, 1991)).
-
- The amines of general formula (I), Diagram 4, in which B represents —CH2— and A, W, X, R19 and R20 are as defined previously, are prepared by reaction of the aldehydes of general formula (VI) with amines of general formula (IV) in reducing medium. The reaction takes place in an alcoholic solvent such as, for example, methanol, and leads to the imine which is then converted to amine by a reducing agent such as NaBH4 or NaBH3CN or also an Amberlite® IRA-400 borohydride resin (Aldrich; 2.5 mmol BH4 −/g of resin).
-
- The compounds of general formula (I), Diagram 5, in which B represents —NH—CO—(CH2)n— and A, W, X, R19, R20 and n are as defined previously, are prepared by reacting amines of general formula (X) with carboxylic acids of general formula (XI) (in which X″ is such that X″—CO═X) according to methods of peptide synthesis described above or also by reacting the same amines of general formula (X) with aldehydes of general formula (XII) (in which X′ is such that X′—CH2═X) under the conditions of reducing amination described above, or also by reacting the same amines of general formula (X) with halogenated derivatives of general formula (XIII) according to standard methods known to a person skilled in the art. The amines of general formula (X) are obtained by condensation of the amines of general formula (VII) with acids of general formula (VIII) in which A, W and n are as defined previously and Gp represents a protective group of the amine function such as, for example, a carbamate group, under standard conditions of peptide synthesis as described above. The amine function is then deprotected (deprotection in acid medium in the case where Gp represents a carbamate group such as, for example, the tert-butoxycarbonyl group).
-
- The carboxamides of general formula (I), Diagram 6, in which B represents —(CH2)p— with p=0, X represents —CO—(CH2)r— and A, W, R19, R20 and r are as defined previously, are prepared by condensation of the acids of general formula (XV), with the amines of general formula (XIV) under standard conditions of peptide synthesis described above.
-
- The compounds of general formula (I), Diagram 7, in which B represents —(CH2)p— with p=0, X represents —(CH2)q—, A, W, R19, R20 and q are as defined previously, are prepared by reaction of the amines of general formula (XIV) with aldehydes of general formula (XVI) under the conditions of reducing amination described above, or by reaction of the same amines of general formula (XIV) with halogenated derivatives of general formula (XVII) according to standard methods known to a person skilled in the art.
- 4. Preparation of the Amines of General Formula (IV):
- The amines which are not commercially available of general formula (IV) in which X represents (CH2)q—, W represents H and R19 represents an —SO2—NR23R24 radical (hereafter designated by amines of general formula (IV)s), can in particular be obtained in 6 stages according to methods in the literature, and in particular according to the method represented in Diagram 8 below.
- For example, Diagram 8, the alcohol of general formula (XXI) is obtained in 3 stages from the acid of general formula (XVIII), via sulphonamide by the action of a primary or secondary amine on sulphonyl chloride under the conditions described previously for the synthesis of sulphonamides, followed by esterification, for example by a treatment with trimethylsilyldiazomethane in an alcoholic solvent such as, for example, methanol, and reduction of the ester function by a reducing agent such as LiBH4 in a polar aprotic solvent such as, for example, THF. The alcohol function is then halogenated by CBr4 in the presence of triphenylphosphine, then converted to phthalimide by treatment of potassium phthalimidate in a polar solvent such as, for example, acetonitrile. After cleavage of the phthalimide by addition of hydrazine hydrate in an alcoholic solvent such as, for example, ethanol, the amine of general formula (IV), is obtained.
- The amines of general formula (IV) in which R19 represents the —O—P(O)(OR26)(OR27) group (hereafter designated by amines of general formula (IV)p) can be obtained in 2 stages according to methods in the literature, and in particular, when X represents a —(CH2)q— radical, according to the method represented in Diagram 9 below.
- According to said method, the phenol of general formula (XXIV) is substituted, Diagram 9, using a derivative of phosphonate type, in particular the cyanophosphonate of general formula (XXV), in the presence of a base such as, for example, triethylamine in a solvent such as dichloromethane. The protective group of the amine function (Gp) of the compound of formula (XXVI) is then cleaved under suitable conditions (for example in acid medium in the case where Gp is a group of carbamate type, such as the tert-butoxycarbonyl group) in order to finally produce the amine of general formula (IV)p.
- For the other amines of general formula (IV), a person skilled in the art could for example refer to the PCT Patent Application WO 00/17190.
- 5. Preparation of Certain Starting Reagents:
- Certain starting reagents are not commercially available and should be prepared according to methods described in the literature. By way of example, the preparation of dihydroxy-2-naphthoic acids (A=naphthyl nucleus) can be carried out according to the methods described in Marsilje et al., Bioorg. Med. Chem. Lett. (2000), 10, 477-481.
- The starting reagents in which A represents the phenyl radical substituted by a alkylcarbonyloxy group are obtained from corresponding phenols by the action of a corresponding acid chloride in the presence of a base such as, for example, diisopropylethylamine in a solvent such as dichloromethane.
- The preparation of certain starting reagents will sometimes require the use of protection and deprotection reactions well known to a person skilled in the art who can refer, if necessary, to the following work: T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Second edition (Wiley-Interscience, 1991),
- B) Case where Y Represents an —SO2R30 Radical:
- The compounds of general formula (I) in which Y represents the —SO2—R30 radical (i.e. the compounds of general sub-formula (I).7 in which X represents the —(CH2)q—NH— radical defined previously and the compounds of general sub-formula (I).8 in which the —N(W)—X— group represents an optionally substituted piperazinyl nucleus) can easily be prepared from the amines of general formulae (XXVII) and (XXVII)a (in which A, B, W, R17, R18, q, s and t have the same meaning as in general formula (I)) according to procedures of sulphonamide synthesis as described above (cf. Diagram 10 below).
Preparation of the Amines of General Formula (XXVII) and (XYVII)a: -
- The amines which are not commercially available of general formula (XXVII) or (XXVII)a in which A, B, W, R17, R18, s, t and q are as defined previously are obtained by standard methods by condensation of carboxylic acids of general formula (V) and aldehydes of general formula (VI) with linear diamines of general formula (XXIX) or cyclic diamines of general formula (XXIX)a, Diagram 11, according to methods similar to those described above and in which the protective group Gp of the amine can be a carbamate group such as the tert-butoxycarbonyl group. Cleavage of the protective group is carried out according to known methods, such as for example cleavage in hydrochloric acid medium in the case of the tert-butoxycarbonyl group.
-
- The amines of general formula (XXVII), Diagram 12, in which B represents —(CH2)p— with p=0, X represents —(CH2)q—, A, W and q are as defined previously and Gp is a protective group for an amine function (for example a protective group of carbamate type such as the tert-butoxycarbonyl group), are prepared by reacting the amines of general formula (XIV) with aldehydes of general formula (XXXI) under the conditions of reducing amination described above, or by reacting the same amines of general formula (XIV) with halogenated derivatives of general formula (XXXII) according to standard methods known to a person skilled in the art, followed by a deprotection stage of the intermediate of general formula (XXXIII) carried out under standard conditions known to a person skilled in the art.
- Unless defined otherwise, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications patent applications, all the patents and all other references mentioned here are incorporated by way of reference.
- The following examples are presented in order to illustrate the above procedures and should in no case be considered as a limit to the scope of the invention.
- Characterisation of Certain Compounds by their Retention Time r.t.
- When a retention time r.t. is indicated for the compounds of the examples, this was measured by high performance liquid chromatography combined with mass spectrometry (HPLC-MS) using, according to what is indicated, the following elution conditions:
-
- conditions 1: passage from an acetonitrile-water-trifluoroacetic acid 0-1000-0.2 (A) mixture to an acetonitrile-water-trifluoroacetic acid 850-150-0.2 (B) mixture by a linear gradient over a period of 6 minutes then elution with the pure mixture B for 2 minutes.
- conditions II: passage from an acetonitrile-water-trifluoroacetic acid mixture 100-900-0.2 (A) to an acetonitrile-water-trifluoroacetic acid mixture 850-150-0.2 (B) by a linear gradient over a period of 6 minutes then elution with the pure mixture B for 2 minutes.
- conditions III: passage from an acetonitrile-water-trifluoroacetic acid mixture 50-950-0.2 (A) to an acetonitrile-water-trifluoroacetic acid mixture 900-100-0.2 (B) by a linear gradient over a period of 8.5 min then elution with the pure mixture B for 2 minutes.
- conditions IV: passage from an acetonitrile-water-trifluoroacetic acid mixture 50-950-0.2 (A) to an acetonitrile-water-trifluoroacetic acid mixture 950-50-0 (B) by a linear gradient over a period of 8.5 minutes then elution with the pure mixture B for 10.5 minutes.
- It is a synthesis intermediate obtained during the preparation of the compound of Example 80 of the Application WO 00/17190, N′-(4-{2-[[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]-(methyl)amino]ethyl}-phenyl)-2-thiophenecarboximidamide, according to the procedure described in this document.
- Melting point: 91-93° C.
- MH+=360.30; r.t.=3.40 min (elution conditions I).
- 0.5 g (3 mmol) of 5-(dimethylamino)-2-hydroxybenzaldehyde (Bull. Chem. Soc. Jpn. (1978), 51 (8), 2433-2434) and 0.72 g (3.33 mmol) of N-methyl-2-(4-nitrophenyl)ethylamine hydrochloride are placed in solution in 30 ml of anhydrous methanol under an inert atmosphere in the presence of 0.65 ml of triethylamine (4.5 mmol). The reaction mixture is stirred vigorously for 18 hours before the addition, by portions, of 126 mg (3.33 mmol) of NaBH4. Stirring is maintained for a further 4 hours before adding 10 ml of ice-cold water. The reaction mixture is extracted twice with 50 ml of CH2Cl2. The organic phase is washed with 10 ml of water, dried over sodium sulphate, filtered and concentrated under vacuum. The residue is purified on a silica column (eluent: CH2Cl2/MeOH: 97/3). The expected product is obtained in the form of a brown oil with a yield of 34% (0.34 g).
- NMR 1H (DMSO d6, 200 MHz, δ): 2.23 (s, 3H, CH3); 2.71-2.77 (m, 8H, 2CH3, CH2); 2.96 (t, 3H, CH2); 3.6 (s, 2H, CH2); 6.48-6.53 (m, aromatic 3H's); 7.50-7.55 (m, aromatic 2H's); 8.13-8.17 (m, aromatic 2H's).
- MH+=330.31; r.t.=3.20 min (elution conditions I).
- [It is the compound of Example 11 of the Application WO 00/17190]
- [It is the compound of Example 50 of the Application WO 00/17190]
- 4-(N-methylpiperazinyl)aniline (0.5 g; 2.6 mmol), hydroxybenzotriazole (0.39 g; 2.86 mmol), 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (1.1 g; 5.7 mmol) and triethylamine (0.8 ml; 5.7 mmol) are added to a solution of 0.55 g (2.6 mmol) of 4-(4-nitrophenyl)butanoic acid in dichloromethane (30 ml). The reaction medium is stirred for 16 hours at ambient temperature, then the medium is diluted with 15 ml of water and the product is extracted with dichloromethane. The organic phase is dried over sodium sulphate followed by filtering and concentrating under vacuum and the residue is purified on a silica column (eluent: CH2Cl2/EtOH: 4/1). A clear oil is obtained with a yield of 84% (0.84 g).
- NMR 1H (CDCl3, 100 MHz, δ): 2.0-2.3 (m, 2H, CH2); 2.3-2.5 (m, 5H, CH2, CH3); 2.5-2.7 (m, 4H, 2 CH2); 2.7-3.0 (m, 2H, CH2); 3.1-3.3 (m, 4H, 2CH2); 6.9 (s, 1H, NH); 6.9-7.1 (m, aromatic 2H's); 7.3-7.5 (m, aromatic 4H's); 8.1-8.3 (m, aromatic 2H's).
- 0.1 g of palladium on carbon (10%) is added to a solution of 0.84 g (2.2 mmol) of intermediate 5.1 in a mixture of ethanol (150 ml) and dichloromethane (15 ml). The medium is placed under a hydrogen atmosphere under a pressure of 1.5 bars for 30 minutes. The catalyst is filtered and the solvent is evaporated under reduced pressure. The free base is obtained with a yield of 71% (0.55 g; 1.56 mmol) in the form of a white solid, then placed in solution in ice-cold ethanol (45 ml) and 4.6 ml (4.7 mmol) of a 1N solution of hydrochloric acid in ether is added. After stirring for 30 minutes at ambient temperature, the solvent is evaporated to dryness, then the residue is taken up in ether in order to provide the expected hydrochloride in the form of a clear brown solid with a yield of 97% (0.64 g). Melting point: 156-158° C.
- NMR 1H (DMSO d6, 400 MHz, δ): 1.80-1.88 (m, 2H, CH2); 2.27 (t, 2H, CH2); 2.58 (t, 2H, —CH2); 2.78 (s, 3H, CH3); 3.00-3.80 (m, 8H, 4 CH2); 6.90-6.93 (m, aromatic 2H's); 7.04-7.06 (m, aromatic 2H's); 7.16-7.18 (m, aromatic 2H's); 7.47-7.49 (m, aromatic 2H's); 9.77 (s, 1H, NH).
- MH+=353.23.
- The experimental protocol used is the same as that described for the compound of Example 2, 2-(4-nitrophenyl)ethylamine replacing N-methyl-2-(4-nitrophenyl)ethylamine and 2-hydroxy-3-methoxy-5-(dimethylamino)benzaldehyde replacing 2-hydroxy-5-(dimethylamino)benzaldehyde. A brown oil is obtained. NMR 1H (CDCl3, 400 MHz, δ): 2.85 (m, 6H, N(CH3)2); 2.97 (m, 4H, 2CH2); 3.88 (s, 3H, OCH3); 3.96 (s, 2H, CH2); 6.06-6.07 (d, aromatic 1H); 6.36-6.37 (d, aromatic 1H); 7.36-7.37 (d, aromatic 2H's); 8.17-8.18 (d, aromatic 2H's).
- MH+=346.20; r.t.=3.40 min (elution conditions I).
- The experimental protocol used is the same as that described for the compound of Example 2, 2-(4-nitrophenyl)ethylamine replacing N-methyl-2-(4-nitrophenyl)ethylamine. A brown oil is obtained. NMR 1H (DMSO d6, 400 MHz, δ): 2.71 (m, 6H, N(CH3)2); 2.75-2.89 (m, 4H, 2CH2); 3.76 (s, 3H, CH3); 6.55 (m, 3H, aromatic H); 7.48-7.50 (d, aromatic 2H's); 8.12-8.14 (d, aromatic 2H's).
- MH+=316.26; r.t.=3.30 min (elution conditions I).
- The experimental protocol used is the same as that described for the compound of Example 2,5-(dimethylamino)-4-hydroxy-3-methoxybenzaldehyde, (Bull. Chem. Soc. Jpn. (1978), 51(8), 2433-2434; replacing 5-(dimethylamino)-3-methoxy-2-hydroxybenzaldehyde. A brown oil is obtained.
- NMR 1H (DMSO d6, 400 MHz, δ): 2.61-2.64 (m, 2H, CH2); 2.71 (m, 6H, N(CH3)2); 2.88-2.90 (m, 2H, CH2); 3.66 (s, 2H, CH2); 7.14-7.17 (m, aromatic 2H's); 7.48-7.51 (m, aromatic 2H's); 8.13-8.15 (m, aromatic 2H's).
- MH+=360.27; r.t.=3.30 min (elution conditions I);
- The experimental protocol used is the same as that described for the compound of Example 2, 2,5-dihydroxybenzaldehyde replacing 5-(dimethylamino)-3-methoxy-2-hydroxybenzaldehyde. A brown oil is obtained.
- NMR 1H (DMSO d6, 400 MHz, δ): 2.22 (s, 3H, CH3); 2.74 (t, 2H, CH2); 2.95 (t, 2H, CH2); 3.57 (s, 2H, CH2); 6.48 (m, aromatic 3H's); 7.50-7.52 (d, aromatic 2H's); 8.13-8.15 (d, aromatic 2H's).
- MH+=303.25; r.t.=3.80 min (elution conditions I).
- 0.1 g (0.278 mmol) of 4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]-amino}methyl)phenol (compound of Example 1) are placed in solution in 5 ml of anhydrous dichloromethane in the presence of 49 μl (0.42 mmol; 1.5 eq.) of diisopropylethylamine at 0° C. 30 μl (0.42 mmol; 1.5 eq.) of acetyl chloride are added dropwise to the solution and the medium is stirred for 1 hour at ambient temperature. Then 10 ml of dichloromethane is added to the reaction medium which is then washed with 3
times 10 ml of a saturated solution of sodium chloride. The organic phase is dried over magnesium sulphate, followed by filtering and concentrating under vacuum. The residue is purified on a silica column (eluent: AcOEt/Heptane: 2/1) in order to produce a yellow oil with a yield of 60%. - NMR 1H (DMSO d6, 400 MHz, δ): 2.16 (m, 6H, 2N(CH3)2); 2.59 (t, 2H, CH2); 2.80 (m, 6H, 2 CH3); 2.87 (t, 2H, CH2); 3.31 (s, 2H, CH2); 3.71 (s, 3H, OCH3); 6.11 (s, aromatic 1H); 6.27 (s, aromatic 1H); 7.48 (m, aromatic 2H's); 8.11 (m, aromatic 2H's).
- MH+=402.19; r.t.=4.80 min (elution conditions I).
- 125 μl of 4-nitrophenethylamine (1 mmol), 1 ml of a 1M solution of N,N′-dicyclohexylcarbodiimide in dichloromethane and 135 mg (1 mmol) of hydroxybenzotriazole monohydrate are added successively to a solution of 204 mg (1 mmol) of 3,7-dihydroxy-2-naphthoic acid in dimethylformamide (10 ml). The reaction mixture is stirred for two hours at ambient temperature, followed by diluting with 100 ml of water and extracting twice with 30 ml of ethyl acetate. The organic phases are combined then washed successively with 100 ml of water then with 50 ml of a saturated solution of sodium chloride. The organic phase is dried over magnesium sulphate, followed by filtering and the solvent is eliminated by evaporation under reduced pressure. The residue is taken up in dichloromethane followed by filtering and drying under vacuum. 100 mg of product is obtained in the form of a yellow powder (yield of 30%). Melting point: >250° C.
- MH+=353.20; r.t.=6.10 min (elution conditions I).
- The experimental protocol used is the same as that described for the compound of Example 11, 4-dimethylaminobenzylamine replacing 4-nitrophenethylamine. A yellow oil is obtained.
- NMR-1H (DMSO d6, 400 MHz, δ): 2.86 (s, 6H); 4.42 (s, 2H); 6.70 (m, 2H); 7.04-7.20 (m, 5H); 7.58 (d, 1H); 8.29 (s, 1H); 9.32 (t, 1H); 9.55 (s, 1H); 11.78 (s, 1H).
- MH+=337.20; r.t.=4.20 min (elution conditions I).
- 1.2 g (5 mmol) of N-Boc tyramine, 0.9 g (5.5 mmol) of diethylcyanophosphonate and 1.4 ml (10 mmol) of triethylamine are placed in solution in 5 ml of dichloromethane at 0° C. under an argon atmosphere. The reaction mixture is stirred for 30 minutes at 0° C. followed by diluting with 25 ml of water and extracting with twice 30 ml of dichloromethane. The organic phases are combined followed by washing with 50 ml of water then 25 ml of a saturated solution of sodium chloride. The organic phase is dried over magnesium sulphate, followed by filtering and concentrating under vacuum. The expected product is obtained in the form of a clear oil with a yield of 92% (1.73 g).
- 1.7 g (4.5 mmol) of intermediate 13.1 is dissolved in 20 ml of a 4M solution of hydrochloric acid in dioxane. The reaction mixture is stirred for 1 hour at ambient temperature then concentrated under reduced pressure. 20 ml of a saturated solution of sodium hydrogen carbonate is added to the reaction mixture which is then extracted twice with 25 ml of ethyl acetate. The desired compound is obtained with a yield of 62% (0.76 g) and is used in the following stage without other purification.
- The experimental protocol used is the same as that described for the compound of Example 11, intermediate 13.2 replacing 4-nitrophenethylamine. A yellow powder is obtained. Melting point: 192-194° C.
- MH+=460.20; r.t.=9.60 min (elution conditions I).
- The experimental protocol used is the same as that described for the compound of Example 11, 4-(2-aminoethyl)benzenesulphonamide replacing 4-nitrophenethyl amine. A yellow oil is obtained.
- NMR-1H (DMSO d6, 400 MHz, δ): 2.98 (t, 2H); 3.59 (q, 2H); 7.05-7.09 (m, 2H); 7.14 (s, 1H); 7.28 (s, 2H); 7.46 (d, 2H); 7.58 (d, 1H); 7.75 (d, 2H); 8.22 (s, 1H); 9.03 (t, 1H); 9.55 (s, 1H); 11.64 (s, 1H).
- MH+=387.10; r.t.=4.30 min (elution conditions I).
- It is a synthesis intermediate from obtained during the preparation of the compound of Example 11 of the Application WO 00/17190, 2,7-dihydroxy-N-{2-[4-[(2-thienyl (imino)methyl)amino]phenyl]ethyl}-2-naphthalenecarboxamide, according to the procedure described in this document. A beige solid is obtained.
- MH+=323.20; r.t.=4.00 min (elution conditions I).
- 44 μl (0.55 mmol) of methanesulphonyl chloride is added to a solution of 170 mg (0.5 mmol) of the compound of Example 15 in pyridine (1 ml). The reaction medium is stirred for 16 hours at ambient temperature then diluted with 20 ml of water and extracted twice with 30 ml of ethyl acetate. The organic phases are combined followed by washing successively with 20 ml of water then 20 ml of a saturated solution of sodium chloride. The organic phase is dried over magnesium sulphate, followed by filtering and the solvent is eliminated by evaporation under reduced pressure. The residue is eluted on silica with a mixture of ethyl acetate and dichloromethane (30/70). 65 mg of product is obtained (yield of 30%) in the form of a yellow powder. Melting point: 176-178° C.
- MH+=401.10; r.t.=4.60 min (elution conditions II).
- The compounds of Examples 17 to 28 are synthesized according to the same strategy as that used for the compound of Example 16.
- Yellow powder. Melting point: 193-195° C.
- MH+=443.20; r.t.=5.50 min (elution conditions II).
- Yellow powder. Melting point: 182-184° C.
- MH+=477.20; r.t.=5.70 min (elution conditions II).
- Yellow oil.
- MH+=513.20; r.t.=9.70 min (elution conditions III).
- Yellow oil.
- MH+=531.20; r.t.=9.60 min (elution conditions III).
- Yellow oil.
- MH+=477.20; r.t.=9.20 min (elution conditions III).
- Brown oil.
- MH+=531.20; r.t.=9.80 min (elution conditions III).
- Orange-coloured oil.
- MH+=508.20; r.t.=9.30 min (elution conditions III).
- Brown oil.
- MH+=531.20; r.t.=9.80 min (elution conditions III).
- Yellow oil.
- MH+=469.20; r.t.=9.00 min (elution conditions III).
- Yellow oil.
- MH+=493.20; r.t.=9.10 min (elution conditions III).
- Yellow oil.
- MH+=467.20; r.t.=7.90 min (elution conditions III).
- Yellow oil.
- MH+=481.20; r.t.=9.20 min (elution conditions III).
- 11 g (50 mmol) of 3-chlorosulphonylbenzoic acid in suspension in dichloromethane (300 ml) is treated with 12.4 g (125 mmol) of 4-methylpiperidine and the reaction mixture is maintained under stirring at ambient temperature overnight. The resulting solution is washed successively with a 10% aqueous solution of citric acid and a saturated solution of sodium chloride, followed by drying (Na2SO4) and concentrating under reduced pressure in order to produce a colourless viscous residue. The latter is taken up in methanol and, whilst maintaining the temperature between 0° C. and 10° C., is titrated by trimethylsilyldiazomethane until a characteristic yellow coloration persists. The excess reagent is destroyed with a few drops of formic acid, and the reaction medium is concentrated under reduced pressure. The traces of acid and methanol are eliminated by two azeotropic evaporations under reduced pressure with toluene. The residue, taken up in tetrahydrofuran (300 ml), is treated with lithium borohydride (2N in THF, 30 ml). The reaction medium is taken to reflux for 2 hours then cooled down and hydrolyzed with a saturated solution of ammonium chloride. The resulting mixture is extracted with ethyl acetate then the organic phase is washed with a saturated solution of sodium chloride, followed by drying (Na2SO4) and concentrating under reduced pressure. The residue is purified on a silica column (eluent: 5% acetone in dichloromethane) in order to produce the expected benzyl alcohol in the form of a white solid.
- NMR 1H (DMSO d6, 400 MHz, δ): 0.84 (d, 3H); 1.13 (m, 2H); 1.26 (m, 1H); 1.63 (d, 2H); 2.17 (t, 2H); 3.59 (d, 2H); 4.59 (d, 2H); 5.42 (t, 1H); 7.60 (m, 3H); 7.67 (s, 1H).
- 950 mg (3.5 mmol) of benzyl alcohol, 1.5 equivalents of triphenylphosphine and 1.5 equivalents of phthalimide in solution in dichloromethane (50 ml) are treated with 1.5 equivalents of diisopropyl diazadicarboxylate and the reaction mixture is stirred overnight at ambient temperature, then treated with a saturated solution of ammonium chloride, washed with a saturated solution of sodium chloride, followed by drying (Na2SO4) and concentrating under reduced pressure. The residue is purified on a silica column (eluent: EtOAc/
heptane 1/4) in order to produce a white solid. - NMR 1H (DMSO d6; 400 MHz, δ): 0.79 (d, 3H); 1.05 (m, 2H); 1.26 (m, 1H); 1.57 (d, 2H); 2.18 (t, 2H); 3.56 (d, 2H); 4.89 (s, 2H); 7.6 (m, 3H); 7.68 (s, 1H); 7.88 (m, 4H).
- Intermediate 29.2 is treated with an excess of hydrazine hydrate in methanol and the resulting mixture is maintained under stirring at ambient temperature overnight, then concentrated under reduced pressure. The residue taken up in dichloromethane is washed with a saturated solution of sodium chloride. After drying and concentrating, a white solid is obtained which is purified on a silica column (eluent: 10% MeOH/DCM) in order to produce a white solid.
- NMR 1H (DMSO-d6, 400 MHz, δ): 0.84 (d, 3H); 1.13 (m, 2H); 1.26 (m, 1H); 1.63 (d, 2H); 2.17 (t, 2H); 3.58 (d, 2H); 4.22 (d, 2H); 7.6 (m, 3H); 7.70 (s, 1H).
- The experimental protocol used is the same as that described for the compound of Example 11, intermediate 29.3 replacing 4-nitrophenethylamine.
- NMR 13C (DMSO-d6, 100 MHz, δ): 21.4; 29.39; 32.90; 42.41; 46.19; 109.22; 111.06; 118.89; 121.59; 126.06; 126.14; 127.47; 127.57; 128.07; 129.58; 130.89; 132.15; 136.01; 140.98; 153.00; 153.67; 168.58.
- MH+=455.20; r.t.=9.90 min (elution conditions IV).
- The experimental protocol used is the same as that described for intermediate 5.1), N,N-dimethyl-1,2-benzenediamine replacing 4-(N-methylpiperazinyl)aniline and 5-(4-nitropheny)pentanoic acid replacing 4-(4-nitrophenyl)butanoic acid.
- The experimental protocol used is the same as that described for intermediate 5.2, intermediate 30.1 replacing intermediate 5.1.
- 0.071 g (0.24 mmol) of S-methyl-2-thiophenethiocarboximide hydroiodide (Ann. Chim. (1962), 7, 303-337) is added to a solution of 0.07 g (0.22 mmol) of intermediate 30.2 in 2-propanol (5 ml). After heating at 60° C. for 18 hours, the reaction mixture is concentrated to dryness under reduced pressure. The residue is taken up in ethyl acetate and a saturated solution of sodium carbonate. After decanting, the organic phase is washed successively with twice 25 ml of water and twice 25 ml of a saturated solution of sodium chloride. The organic phase is dried over magnesium sulphate followed by filtering and evaporating under reduced pressure. The evaporation residue is purified on a silica column (eluent: ethyl acetate/heptane: 2/1). 0.06 g (yield of 63%) of a free base is obtained. The hydrochloride is prepared by dissolving 0.06 g (0.14 mmol) of the previously obtained base in acetone (10 ml) and by adding 0.43 ml of a molar solution of hydrochloric acid in anhydrous diethyl ether to it. The crystals obtained are filtered and rinsed with diethyl ether in order to produce, after drying, 0.052 g of the desired product (yield of 74%) in the form of a beige solid. Melting point: 145-148° C. MH+=421.20; r.t.=3.30 min (elution conditions II).
- The experimental protocol used is the same as that described for the compound of Example 11, N-tert-butyloxycarbonylpiperazine replacing 4-nitrophenethylamine. A beige solid is obtained.
- 10 ml of a 4N solution of hydrochloric acid in dioxane is added to a solution of 1.9 g (5 mmol) of intermediate 31.1 in ethanol (20 ml). The solution is stirred for 2 hours at ambient temperature, the solvent is evaporated off and the residue is taken up in dichloromethane. The precipitate is filtered followed by washing with dichloromethane and drying under vacuum. 1.35 g of the expected product is obtained in the form of a white powder.
- The experimental protocol used is the same as that described for the compound of Example 16, intermediate 31.2 replacing the compound of Example 15 and paratoluene sulphonyl chloride replacing methane sulphonyl chloride. A yellow powder is obtained.
- Melting point: 135-137° C.
- MH+=427.20; r.t.=8.30 min (elution conditions IV).
- The compounds of Examples 32 and 33 are synthesized according to the same strategy as that used for the compound of Example 31.
- Yellow powder. Melting point: 124-126° C.
- MH+=351.20; r.t.=6.70 min (elution conditions IV).
- Yellow powder. Melting point: 105-110° C.
- MH+=393.20; r.t.=7.90 min (elution conditions IV).
- Pharmacological Study of the Compounds of the Invention
- Test Protocols
- a) Measurement of the Phosphatase Activity of the Purified Cdc25C Recombinant Enzyme
- The phosphatase activity of the MBP-Cdc25C protein is evaluated by the dephosphorylation of 3-O-methylfluorescein-phosphate (OMFP) to 3-O-methylfluorescein (OMF) with determination of the fluorescence of the reaction product at 475 nm. This test allows identification of the inhibitors of cdc25 recombinant enzyme. The preparation of the fusion protein MBP-cdc25C is described in PCT Patent Application WO 01/44467.
- The reaction is carried out in 384-well plate format in a final volume of 50 μl. The MBP-Cdc25C protein (prepared as described above) is stored in the following elution buffer: 20 mM Tris-HCl pH 7.4; 250 mM NaCl; 1 mM EDTA; 1 mM DTT; 10 mM maltose. It is diluted to a concentration of 60 μM in the following reaction buffer: 50 mM Tris-HCl pH 8.2; 50 mM NaCl; 1 mM DTT; 20% glycerol. Measurement of the background noise is carried out with the buffer without addition of the enzyme. The products are tested at decreasing concentrations starting from 80 μM. The reaction is initiated by the addition of an OMFP solution at 500 μM final (prepared beforehand from a 12.5 mM stock solution in 100% DMSO (Sigma #M2629)). After 4 hours at 30° C. in a disposable 384-well plate, the fluorescence measured at OD 475 nm is read using a Victor2 plate reader (EGG-Wallac). Determination of the 50% inhibitory concentration of the enzymatic reaction is calculated from three independent experiments. Only the values included in the linear part of the sigmoid are retained for linear regression analysis.
- b) Measurement of the State of cdc2 Phosphorylation:
- This relates to showing that the enzymatic activity of cdc25-C phosphatase is inhibited in vivo on the purified enzyme in the presence of selected inhibitors. When cdc25-C is inhibited, the quantity of phosphorylated cdc2 protein (inactive) increases.
- The cells of the Mia PaCa2 line are seeded at a rate of 450 000 cells in 10 cm Petri dishes in Dulbecco's modified Eagle medium completed with 10% foetal calf serum 48 hours later, the cells are treated for 1 hour with the compound to be tested or menadione at 100 μM (reference inhibitor). The medium is renewed after washing with PBS. 24 hours after the cells are scraped and lysed in the lysis buffer (
Hepes 50 mM pH 7.5;NaCl 10 mM;Triton X100 1%;glycerol 10%; MgCl2 5 mM;EDTA 1 mM;sodium orthovanadate 1 mM; protease inhibitor cocktail 1836170 Roche Diagnostics). After centrifugation at 13 000 rpm for 10 minutes at 4° C., the concentration of proteins is, determined in the supernatant (Bio-Rad DC Protein assay kit) and adjusted to 10 μg. The load buffer concentrated 5 times (TrisHCl 125 mM pH 7.4;SDS 10%;glycerol 50%; bromophenol blue 0.025%; β-mercaptoethanol 7%) is added to the samples. The samples are heated for 10 minutes at 100° C. The samples are deposited in a volume of 40 μl on Tris/Glycine 12% gels (BioRad). Migration occurs over 1 hour at 180 V. The proteins are transferred onto a nitrocellulose membrane (Hybond C, Amersham) under semi-dry conditions. The membrane is blocked for 1 hour in milk (BioRad) at 5% with 0.1% Tween 20. Then it is incubated for 6 hours with the primary antibody directed against phosphorylated cdc2 (PhosphoPlus cdc2, 91115 New England BioLabs) diluted to 1/1300th. After washing in PBS-Tween 20 at 0.1%, the membrane is incubated for 1 hour and 30 minutes with the secondary antibody anti-rabbit Immunoglobulin G (anti-rabbit IgG-HRP, sc2030, Santa Cruz) diluted to 1/40000th. The proteins are revealed by electrochemical luminescence (western blotting detection system ECL+, Amersham) which is detected using photographic films (BioMax light, Sigma). The images are scanned (BioProfil scanner, Vilbert Lourmat) and processed in Powerpoint®. The result obtained is reproduced inFIG. 1 which represents the comparative effect of menadione and the compound of Example 1 on the phosphorylation of cdc2 in the Mia PaCa-2 line (3 hour treatment with menadione or the compound of Example 1 and sampling 24 hours later). - c) Characterization of the Anti-Proliferative Activity:
- By way of example, the effect of a treatment on two lines of human Mia-Paca2 and DU145 cells with compounds of Examples 1-5 described previously will be studied. The cell lines DU145 (human prostate cancer cells) and Mia-PaCa2 (human pancreatic cancer cells) were acquired from the American Tissue Culture Collection (Rockville, Md., USA). The cells placed in 80 μl of Dulbecco's modified Eagle medium (Gibco-Brl, Cergy-Pontoise, France) completed with 10% foetal calf serum inactivated by heating (Gibco-Brl, Cergy-Pontoise, France), 50000 units/l of penicillin and 50 mg/l streptomycin (Gibco-Brl, Cergy-Pontoise, France), and 2 mM of glutamine (Gibco-Brl, Cergy-Pontoise, France) were seeded on a 96-well plate on day 0. The cells were treated on
day 1 for 96 hours with increasing concentrations of each of the compounds to be tested up to 50 μg/ml. At the end of this period, quantification of cell proliferation is evaluated by a colorimetric test based on the cleavage of the tetrazolium salt WST1 by mitochondrial dehydrogenases in viable cells leading to the formation of formazan (Boehringer Mannheim, Meylan, France). These tests are carried out in duplicate with 8 determinations per concentration tested. For each compound to be tested, the values included in the linear part of the sigmoid were retained for linear regression analysis and used to estimate the inhibitory concentration IC50. The products are solubilized in dimethylsulphoxide (DMSO) at 10−2 M and finally used in culture with 0.5% DMSO. - Results of the Tests
- a) The compounds of Examples 1 to 11, 13 to 18 and 27 to 33 present an IC50 lower than or equal to 100 μM on the phosphatase activity of the purified Cdc25-C recombinant enzyme.
- b) The inhibitory activity of the compound of Example 1 on the endogenous cdc25C phosphatase of human cells is shown by the growing increase of the phosphorylated form of cdc2 in the Mia-Paca2 cells treated with increasing concentrations of this compound. This increase is comparable to that induced by menadione (see
FIG. 1 ). - c) The compounds of Examples 1 to 4, 6 to 11, 13, 14, 16 to 18, 22 and 28 to 31 present an IC50 lower than or equal to 100 μM on the cell proliferation of Mia-Paca2 lines.
- d) The compounds of the examples 1 to 4, 8 to 10, 13, 14, 16 to 18, 22 and 28 to 30 present an IC50 lower than or equal to 100 μM on the cell proliferation of DU-145 lines.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/410,659 US20060235027A1 (en) | 2000-07-28 | 2006-04-25 | Inhibitors of cdc25 phosphatases |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0009900A FR2812198B1 (en) | 2000-07-28 | 2000-07-28 | AMIDINE DERIVATIVES INHIBITORS OF PHOSPHATASES cdc25 |
FR00/09900 | 2000-07-28 | ||
US10/343,171 US7196084B2 (en) | 2000-07-28 | 2001-07-26 | Cdc25 phosphatase inhibitors |
PCT/FR2001/002443 WO2002009686A2 (en) | 2000-07-28 | 2001-07-26 | Cdc25 phosphatase inhibitors |
US11/410,659 US20060235027A1 (en) | 2000-07-28 | 2006-04-25 | Inhibitors of cdc25 phosphatases |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/002443 Division WO2002009686A2 (en) | 2000-07-28 | 2001-07-26 | Cdc25 phosphatase inhibitors |
US10/343,171 Division US7196084B2 (en) | 2000-07-28 | 2001-07-26 | Cdc25 phosphatase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060235027A1 true US20060235027A1 (en) | 2006-10-19 |
Family
ID=8853011
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/343,171 Expired - Fee Related US7196084B2 (en) | 2000-07-28 | 2001-07-26 | Cdc25 phosphatase inhibitors |
US11/350,692 Abandoned US20060154933A1 (en) | 2000-07-28 | 2006-02-09 | Inhibitors of Cdc25 phosphatases |
US11/410,659 Abandoned US20060235027A1 (en) | 2000-07-28 | 2006-04-25 | Inhibitors of cdc25 phosphatases |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/343,171 Expired - Fee Related US7196084B2 (en) | 2000-07-28 | 2001-07-26 | Cdc25 phosphatase inhibitors |
US11/350,692 Abandoned US20060154933A1 (en) | 2000-07-28 | 2006-02-09 | Inhibitors of Cdc25 phosphatases |
Country Status (20)
Country | Link |
---|---|
US (3) | US7196084B2 (en) |
EP (2) | EP1370255A2 (en) |
JP (1) | JP2004506618A (en) |
KR (1) | KR20030020414A (en) |
CN (1) | CN100406449C (en) |
AU (3) | AU2001282234B2 (en) |
BR (1) | BR0112824A (en) |
CA (1) | CA2417262A1 (en) |
CZ (1) | CZ2003273A3 (en) |
FR (1) | FR2812198B1 (en) |
HK (1) | HK1063016A1 (en) |
HU (1) | HUP0303828A3 (en) |
IL (2) | IL153999A0 (en) |
IS (1) | IS6701A (en) |
MX (1) | MXPA03000860A (en) |
NO (1) | NO20030421L (en) |
NZ (1) | NZ523739A (en) |
PL (1) | PL365074A1 (en) |
RU (1) | RU2285521C2 (en) |
WO (1) | WO2002009686A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080208594A1 (en) * | 2007-02-27 | 2008-08-28 | Cross Charles W | Effecting Functions On A Multimodal Telephony Device |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2812198B1 (en) * | 2000-07-28 | 2008-07-18 | Sod Conseils Rech Applic | AMIDINE DERIVATIVES INHIBITORS OF PHOSPHATASES cdc25 |
FR2856688B1 (en) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUCT COMPRISING AT LEAST ONE CDC25 PHOSPHATASE INHIBITOR IN ASSOCIATION WITH AT LEAST ONE ANOTHER CANCER AGENT |
FR2915747B1 (en) * | 2007-05-04 | 2011-02-25 | Scras | TRI-AMINO-PYRIMIDINE DERIVATIVES AS CDC25 PHOSPHATASE INHIBITORS |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4032635A (en) * | 1975-06-12 | 1977-06-28 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pharmaceutical method for the therapy of immune diseases |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2193015A (en) * | 1939-05-24 | 1940-03-12 | Eastman Kodak Co | Developer containing sulphonamide groups |
US2652428A (en) * | 1951-05-05 | 1953-09-15 | Eastman Kodak Co | N-alkyl-n-(beta-methylsulfonamidoethyl)-p-aminophenols |
JPS525486B2 (en) * | 1973-02-13 | 1977-02-14 | ||
LU68988A1 (en) * | 1973-12-12 | 1975-08-20 | ||
US4032632A (en) * | 1976-07-23 | 1977-06-28 | Pfizer Inc. | Mixture of antibiotics produced by new species of streptosporangium |
FR2364204A1 (en) * | 1976-09-09 | 1978-04-07 | Oreal | NEW METAAMINOPHENOLS AND TINCTORIAL COMPOSITIONS CONTAINING THEM |
AU567140B2 (en) * | 1984-01-06 | 1987-11-12 | Shionogi & Co., Ltd. | Sulphonamido-benzamide derivatives |
JPH0273068A (en) * | 1988-09-09 | 1990-03-13 | Asahi Chem Ind Co Ltd | Novel phenethylamine derivative and acid addition salt thereof |
GB8914660D0 (en) * | 1989-06-26 | 1989-08-16 | Fujisawa Pharmaceutical Co | Aniline derivatives,processes for production thereof and pharmaceutical compositions comprising the same |
WO1995005363A1 (en) * | 1993-08-12 | 1995-02-23 | Astra Aktiebolag | Amidine derivatives with nitric oxide synthetase activities |
JPH0844011A (en) * | 1994-07-29 | 1996-02-16 | Fuji Photo Film Co Ltd | Silver halide color photographic sensitive material |
US5741819A (en) * | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
AU1328197A (en) * | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
FR2761066B1 (en) * | 1997-03-24 | 2000-11-24 | Sod Conseils Rech Applic | NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
GB9800750D0 (en) * | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
FR2783519B1 (en) * | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2812198B1 (en) * | 2000-07-28 | 2008-07-18 | Sod Conseils Rech Applic | AMIDINE DERIVATIVES INHIBITORS OF PHOSPHATASES cdc25 |
-
2000
- 2000-07-28 FR FR0009900A patent/FR2812198B1/en not_active Expired - Fee Related
-
2001
- 2001-07-26 JP JP2002515239A patent/JP2004506618A/en active Pending
- 2001-07-26 BR BR0112824-8A patent/BR0112824A/en not_active Application Discontinuation
- 2001-07-26 CZ CZ2003273A patent/CZ2003273A3/en unknown
- 2001-07-26 KR KR10-2003-7001208A patent/KR20030020414A/en not_active Application Discontinuation
- 2001-07-26 HU HU0303828A patent/HUP0303828A3/en unknown
- 2001-07-26 EP EP01960837A patent/EP1370255A2/en not_active Withdrawn
- 2001-07-26 US US10/343,171 patent/US7196084B2/en not_active Expired - Fee Related
- 2001-07-26 AU AU2001282234A patent/AU2001282234B2/en not_active Ceased
- 2001-07-26 AU AU8223401A patent/AU8223401A/en active Pending
- 2001-07-26 MX MXPA03000860A patent/MXPA03000860A/en active IP Right Grant
- 2001-07-26 CN CNB018149545A patent/CN100406449C/en not_active Expired - Fee Related
- 2001-07-26 CA CA002417262A patent/CA2417262A1/en not_active Abandoned
- 2001-07-26 IL IL15399901A patent/IL153999A0/en active IP Right Grant
- 2001-07-26 RU RU2003105689/15A patent/RU2285521C2/en not_active IP Right Cessation
- 2001-07-26 NZ NZ523739A patent/NZ523739A/en unknown
- 2001-07-26 PL PL01365074A patent/PL365074A1/en unknown
- 2001-07-26 EP EP05018614A patent/EP1602368A3/en not_active Withdrawn
- 2001-07-26 WO PCT/FR2001/002443 patent/WO2002009686A2/en active IP Right Grant
-
2003
- 2003-01-16 IL IL153999A patent/IL153999A/en not_active IP Right Cessation
- 2003-01-27 NO NO20030421A patent/NO20030421L/en not_active Application Discontinuation
- 2003-01-27 IS IS6701A patent/IS6701A/en unknown
-
2004
- 2004-08-06 HK HK04105845.2A patent/HK1063016A1/en not_active IP Right Cessation
-
2006
- 2006-02-09 US US11/350,692 patent/US20060154933A1/en not_active Abandoned
- 2006-04-25 US US11/410,659 patent/US20060235027A1/en not_active Abandoned
- 2006-10-24 AU AU2006233164A patent/AU2006233164B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4032635A (en) * | 1975-06-12 | 1977-06-28 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pharmaceutical method for the therapy of immune diseases |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080208594A1 (en) * | 2007-02-27 | 2008-08-28 | Cross Charles W | Effecting Functions On A Multimodal Telephony Device |
Also Published As
Publication number | Publication date |
---|---|
JP2004506618A (en) | 2004-03-04 |
WO2002009686A3 (en) | 2003-10-09 |
AU2001282234B2 (en) | 2006-07-27 |
RU2285521C2 (en) | 2006-10-20 |
US20060154933A1 (en) | 2006-07-13 |
NO20030421L (en) | 2003-03-19 |
HK1063016A1 (en) | 2004-12-10 |
BR0112824A (en) | 2004-02-10 |
AU8223401A (en) | 2002-02-13 |
KR20030020414A (en) | 2003-03-08 |
NO20030421D0 (en) | 2003-01-27 |
HUP0303828A3 (en) | 2007-10-29 |
US7196084B2 (en) | 2007-03-27 |
CZ2003273A3 (en) | 2003-06-18 |
EP1602368A3 (en) | 2009-09-02 |
HUP0303828A2 (en) | 2004-03-01 |
US20040034103A1 (en) | 2004-02-19 |
FR2812198B1 (en) | 2008-07-18 |
AU2006233164A1 (en) | 2006-11-09 |
WO2002009686A2 (en) | 2002-02-07 |
CN100406449C (en) | 2008-07-30 |
NZ523739A (en) | 2005-09-30 |
CN1474689A (en) | 2004-02-11 |
IL153999A (en) | 2007-07-04 |
EP1370255A2 (en) | 2003-12-17 |
IL153999A0 (en) | 2003-07-31 |
EP1602368A2 (en) | 2005-12-07 |
IS6701A (en) | 2003-01-27 |
PL365074A1 (en) | 2004-12-27 |
CA2417262A1 (en) | 2002-02-07 |
MXPA03000860A (en) | 2003-06-06 |
FR2812198A1 (en) | 2002-02-01 |
AU2006233164B2 (en) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9580398B2 (en) | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | |
EP3094332B1 (en) | Carbonyl erastin analogs and their use | |
US10745386B2 (en) | Coumarin based HSP90 inhibitors with urea and ether substituents | |
US20120100592A1 (en) | Pipemidic acid derivative autotaxin inhibitors | |
US20060235027A1 (en) | Inhibitors of cdc25 phosphatases | |
US11591301B2 (en) | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | |
Tangadanchu et al. | Structure-activity relationship studies and bioactivity evaluation of 1, 2, 3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors | |
WO2018189679A1 (en) | Isoindoline derivatives for use as ampk activators | |
US20130274283A1 (en) | Premature-termination-codons readthrough compounds | |
JP2019515049A (en) | Novel 2,4,6-trisubstituted s-triazine compounds and method for producing and using the same | |
US7049468B2 (en) | Modulators of Rho C activity | |
WO2002059125A1 (en) | Cyclin dependent kinase inhibiting purine derivatives | |
EP3315495A1 (en) | N,n' -diarylurea, n,n' -diarylthiourea and n,n' -diarylguanidino compounds for use in treatment and prevention of inflammatory disease | |
US11124490B2 (en) | Autotaxin inhibitors | |
US20210137946A1 (en) | Ursodeoxycholic acid derivatives for the treatment of polycystic diseases | |
US20230225991A1 (en) | Compounds for use in the treatment of acute intermittent porphyria | |
US11607419B2 (en) | Inhibitors of RAC1 and uses thereof for inducing bronchodilatation | |
US20220306603A1 (en) | Targeting dna repair in tumor cells via inhibition of ercc1-xpf | |
US20020183393A1 (en) | Inhibitors of Rho C | |
Paolini et al. | Preparation of isoindoline derivatives for use as AMPK activators | |
EP3381897A1 (en) | Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer | |
AU2002228155A1 (en) | Cyclin dependent kinase inhibiting purine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IPSEN PHARMA S.A.S., FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:SOCIETE DE CONSEILS DE RECHERCHES ET D`APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.);REEL/FRAME:022466/0793 Effective date: 20081128 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: IPSEN PHARMA S.A.S., FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 022466 FRAME: 0793. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME;ASSIGNOR:SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.;REEL/FRAME:038628/0931 Effective date: 20081128 |